	Weeks	Daily dose	Niaspan FCT dosage

Initial titration schedule	0 to 4	500 mg	One 500 mg tablet at bedtime

5 to 8	1,000 mg	One 1,000 mg tablet or two 500 mg tablets at bedtime

9 to 12	1,500 mg	One 1,000 mg tablet and one 500 mg tablet at bedtime

13 to 24	2,000 mg	Two 1,000 mg tablets at bedtime


 	Group I(n = 25)	Group P(n = 25)	P value

Desaturation (SpO2 < 90%)	3 (12%)	2 (8%)	1.000

Gastric insufflations	1 (4%)	0 (0%)	1.000

Aspiration	0 (0%)	0 (0%)	—

Laryngospasm	1 (4%)	1 (4%)	1.000

Bronchospasm	0 (0%)	0 (0%)	—

Blood stain	0 (0%)	2 (8%)	0.490


Remaining per-base coverage after B-tail removal	Number of positions with this coverage in the ZR reference (Bv-95nt data)	Number of positions with this coverage in the PhiX reference (PhiX-95nt data)

90 to 100%	41,130 (40.26%)	4,016 (91.65%)

80 to 90%	4,056 (3.97%)	266 (6.07%)

60 to 80%	1,711 (1.67%)	100 (2.28%)

40 to 60%	310 (0.30%)	0 (0.00%)

20 to 40%	76 (0.07%)	0 (0.00%)

0 to 20%	29 (0.03%)	0 (0.00%)


Medical categories	Number of species	Citations	Fic

Tonic	5	38	0.89

Dermatological	4	120	0.97

Gastrointestinal	32	433	0.92

Galactagogue	8	86	0.91

Reproductive	11	155	0.93

Miscellaneous	22	201	0.89

Respiratory disorders	4	37	0.91

Fever	5	41	0.90

Wound healing	7	41	0.85


Marker	Peripheral stroma	Central stroma	Anterior stroma	Posterior stroma

ABCG2	−	−	−	−

ABCG5	−	−	−	−

ALDH1A1	++	++	++	+

α-Actinin	++	++	++	+

CD31	+	+	+	+

CD34	++	++	++	++

CD73	−	−	−	−

CD90	−	−	−	−

CD105	−	−	−	−

Collagen I	++	++	++	++

Collagen IV	−	−	−	−

CXCR4	−	−	−	−

Fibroblast marker	−	−	−	−

Fibronectin	−	−	−	−

Ki-67	−	−	−	−

Nestin	−	−	−	−

VE-Cadherin	−	−	−	−

Vimentin	++	++	++	++


Axis	CoG Position	Linear Acceleration

First Version	Second Version	First Version	Second Version

X	2.4252e−06	1.0008e−06	--*	--*

Y	1.3992e−05	1.3390e−05	6.3191e−06	5.1146e−06

Z	1.5306e−05	4.4980e−06	2.7849e−06	2.3104e−06


	Over-expressed in melan-a v B16	Under-expressed in melan-a v B16	Total

Upregulated by RA treatment	71	14	85

Downregulated by RA treatment	16	132	151

Total	87	149	233


line	gene copy number

WT	0

Sox23	6 (12 homozygous)

Sox42	1 (2 homozygous)

Sox44	2 (4 homozygous)


Index	Placebo group	Zaleplon 10 mg group	Zaleplon 15 mg group

Scores of SQS	3.75 ± 1.04	5.38 ± 0.92**	6.00 ± 0.76**

Scores of SDS	3.25 ± 1.04	4.62 ± 1.41*	6.12 ± 0.83**∆

Scores of SSS	2.38 ± 0.92	2.12 ± 0.64	2.38 ± 0.92


Characteristic	No. of patients	%

Patients evaluable	40	100

Age, years

 Median	65

 Range	34–75

Sex

 Male	24	60

 Female	16	40

ECOG PS

 0	6	15

 1	27	67.5

 2	7	17.5

Disease location

 Gastric	30	75

 GEJ	10	25

Histologic type

 Diffuse	19	47.5

 Intestinal	15	37.5

 Unspecified	6	15

Previous adjuvant chemotherapy	6	15

Status of primary tumor

 Unresected	28	70

 Resected	12	30

Predominant site of disease

 Liver	24	60

 Peritoneum	8	20

 Nodes	4	10

 Lung	2	5

 Bone	2	5

No. of metastatic sites

 1	11	27.5

 2	19	47.5

 ≥ 3	10	25


Patient	Karyotype/Molecular lesion(s)	FAB subgroup	Age at diagnosis	IDO1 status	CR	Relapse	Alive

UPN #1	Normal	M2	13.0	Negative	Yes	No	Yes

UPN #2	t(8;21) (q22;q22)	M2	13.0	Negative	Yes	No	Yes

UPN #3	Normal	M1	10.0	Negative	Yes	No	Yes

UPN #4	Normal	M2	4.9	Negative	Yes	No	Yes

UPN #5	Normal	M5	12.0	Negative	Yes	No	Yes

UPN #6	Normal	M1	3.0	Negative	Yes	No	Yes

UPN #7	t(8;21) (q22;q22)	M2	9.0	Negative	Yes	No	Yes

UPN #8	Normal	M1/M2	1.0	Negative	Yes	No	Yes

UPN #9	Normal	M2	15.0	Negative	Yes	No	Yes

UPN #10	N.A.	M1	15.4	Negative	No	Yes	No

UPN #11	Normal	N.A.	N.A.	Negative	No	Yes	No

UPN #12	FLT3-ITD	U	6.0	Negative	No	Yes	Yes

UPN #13	Normal	M2	3.4	Negative	Yes	Yes	Yes

UPN #14	t(6;9) - FLT3-ITD	M4	23.0	Negative	Yes	Yes	No

UPN #15	Normal	M5	15.5	Negative	Yes	Yes	No

UPN #16	t(8;21) (q22;q22)	M2	11.3	Negative	Yes	Yes	Yes

UPN #17	t(8;21) (q22;q22)	M2	9.0	Negative	Yes	Yes	No

UPN #18	FLT3-ITD	N.A.	14.0	Negative	N.A.	Yes	No

UPN #19	t(9;11)(p22;q23) - MLL-AF9	M5	1.0	Positive	No	No	No

UPN #20	t(10;11) - MLL-AF10	M5	6.0	Positive	Yes	No	Yes

UPN #21	inv(16)(p13q22)	M4	16.0	Positive	Yes	No	No

UPN #22	t(8;21) (q22;q22)	M4	16.0	Positive	Yes	No	Yes

UPN #23	t(10;11) - MLL-AF10	M4/M5	4.0	Positive	Yes	No	Yes

UPN #24	FLT3-ITD	M4	12.3	Positive	Yes	No	Yes

UPN #25	inv(16) (p13q22)	M4	17.2	Positive	Yes	No	Yes

UPN #26	t(1;11) - MLL-AF1	M5	0.2	Positive	Yes	No	Yes

UPN #27	inv(16)(p13q22)	M5	9.0	Positive	Yes	No	Yes

UPN #28	Normal	M5	16.5	Positive	N.A.	No	No

UPN #29	FLT3-ITD	M5	7.0	Positive	No	Yes	No

UPN #30	Normal	M5	14.1	Positive	Yes	Yes	No

UPN #31	FLT3-ITD	M5	15.0	Positive	Yes	Yes	No

UPN #32	Normal	M5	0.4	Positive	Yes	Yes	Yes

UPN #33	FLT3-ITD	M5	12.3	Positive	Yes	Yes	No

UPN #34	inv(16) (p13q22)	M4	13.0	Positive	Yes	Yes	Yes

UPN #35	t(10;11) - MLL-AF10	M5	4.0	Positive	Yes	Yes	No

UPN #36	inv(16) (p13q22)	M4	0.8	Positive	Yes	Yes	Yes

UPN #37	FLT3-ITD	M4	15.7	Positive	N.A.	Yes	No


N = 1352	Non-responders n = 909	Responders n = 443	p value

Women, n (%)	520 (57)	273 (62)	0.12 A

Age, average years (SD)	41.3 (11.8)	44.4 (10.8)	0.05 B

Work n (%)			0.15 A

Farming, fishery, industry	150 (17)	65 (15)

Construction, trading and transport	231 (25)	109 (25)

Communication, information, finance, insurance, real estate and consultancy	103 (11)	49 (11)

Public administration, teaching, health, culture and leisure	329 (36)	189 (43)

Other	36 (4)	11 (2)

Missing	60 (7)	20 (5)

Self-reported reason for sickness absence n (%)			<0.001 A

Musculoskeletal disorder (MSD)	387 (43)	244 (55)

Common mental disorder (CMD)	294 (32)	94 (21)

Stress	95 (19)	52 (12)

Functional somatic syndrome/unknown	19 (2)	10 (2)

Heart disorder, lung disorder, cancer	36 (4)	12 (3)

Other	78 (9)	31 (7)

Previous year before inclusion median (iqr)

Employment or unemployment, weeks	42 (26-46)	42 (33-45)	0.35 C

Duration of sickness absence, weeks	7 (5-12)	7 (6-11)	0.43 C

Health care utilization

Visits in general practice	11 (7-18)	12 (7-18)	0.30 C

Visits in physiotherapist clinics	0 (0-0)	0 (0-1)	0.30 C

Visits in out-patient clinics	2 (1-6)	3 (1-6)	0.58 C

Visits in psychiatric out-patient clinics	0 (0-0)	0 (0-0)	0.19 C

Admissions in hospitals	0 (0-0)	0 (0-0)	0.45 C

Admissions in psychiatric hospitals	0 (0-0)	0 (0-0)	0.02 C

One year after inclusion

Labour market participation n (%)			0.92 A

Non-RTW	309 (34)	146 (33)

RTW	548 (60)	273 (62)

Old age and disability pension	50 (6)	22 (5)

Died	2 (0)	2 (0)


	Perianal disease prior to pregnancy n = 27	No perianal disease prior to pregnancy n = 87

Mode of childbirth	Vaginal delivery n (%)	Caesarean section n (%)	Vaginal delivery n (%)	Caesarean section n (%)

	11 (41)	16 (59)	66 (76)	21 (24)

Progression perianal disease ≤ 2 years post partum:	2 (18)	5 (31)	3 (5)	3 (14)

 - Yes	9 (82)	9 (56)	58(94)	18 (86)

 - No	0 (0)	2 (13)	5 (1)	0 (0)

 - Not applicable†


Peptide	Sequence	Mw	pI1	Net charge	Mean hydrophobicity2

KHN20	KHNLGHGHKHERDQGHGHQR	2365.5	9.99	+2	−4.91

GHG20	GHGLGHGHEQQHGLGHGHKF	2127.2	7.21	0	−2.01

GHG21	GHGHKFKLDDDLEHQGGHVLD	2354.5	5.63	−3	−2.32

GGH20	GGHVLDHGHKHKHGHGHGKH	2169.3	9.70	+2	−3.44

HKH20	HKHGHGHGKHKNKGKKNGKH	2151.5	10.78	+7	−5.91

GKH17	GKHKNKGKKNGKHNGWK	1946	10.78	+7	−5.77

GKH17WWW	GKHKNKGKKNGKHNGWKWWW	2505	10.78	+7	−3.45

GKH17WWWWW	GKHKNKGKKNGKHNGWKWWWWW	2287	10.78	+7	−2.25

LL-37	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	4492	10.61	+6	−1.84

Histatin-5	DSHAKRHHGYKRKFHEKHHSHRGY	3036	10.28	+5	−4.67


Matching phase	Type of match	Number linked	%

1	Child’s first, middle, and last name & dob and mother’s dob	5282	2.6 %

2	Child’s first, middle initial, and last name & dob and mother’s dob	32094	16.0 %

3	Child’s first, middle, and last name & dob	3035	1.5 %

4	Child’s first, middle initial, and last name & dob	66730	33.3 %

5	Child’s first and last name & dob	90506	45.2 %

6	Child’s first 3 letters of first name and last name & dob	2696	1.3 %


Number	Authors, year	c	Age, sex	Period (years)	symptoms	Preoperative lab	Treatment	Histological diagnosis	Outcomes

1	Boriani et al, 1978 [8]	S1-3	18, M	DNMI	Bone pain, weakness	Hypophosphatemia, elevated ALP	Complete resection, radiotherapy	Osteosarcoma	NOLF

2	Stone et al, 1992 [9]	T3-4	33, F	DNMI	Bone pain, weakness, fractures	Hypophosphatemia	Complete resection, supplementation of vitamin D, phosphate, and calcium	Neuroendocrine tumor	NOLF

3	Yu et al, 1995 [10]	C2	58, F	DNMI	Musculoskeletal pain, weakness	Hypophosphatemia, elevated ALP and PTH	Partial resection, supplementation of vitamin D and phosphate	PMT	PSA

4	Terek et al, 2001 [11]	S1-2	14, M	1+	Bone pain, skeletal abnormalities	Hypophosphatemia, hypocalcemia, low level of vitamin D3, elevated ALP	Partial resection, chemotherapy (doxorubicin)	Osteosarcoma	PSA, ALL

5	Dissanayake et al, 2003 [37]	L2	58, M	3+	Musculoskeletal pains, fractures	Hypophosphatemia, low level of vit D3, elevated ALP	Complete resection	Haemangiopericytoma	NOLF

6	Folpe et al, 2004 [5]	C1	32, F	4	DNMI	DNMI	Partial resection, radiotherapy	Malignant PMTMCT	PSA recurrence

7	Chua et al, 2008 [12]	T3	34, F	1	Musculoskeletal pain, fatigue	Hypophosphatemia, hypocalcemia, elevated ALP and PTH	Partial resection, supplementation of phosphate and calcitriol	Plasmacytoma	DNMI

8	Sciubba et al, 2009 [13]	T8	56, F	5	Bone pain, weakness, fractures	Hypophosphatemia, low level of vitamin D3, elevated ALP and PTH	Complete resection	PMT	NOLF

9	Pirola et al, 2009 [14]	T4	57, M	DNMI	Fractures, paresthesias	Hypophosphatemia, low level of vitamin D3, elevated ALP and PTH	Complete resection, supplementation of vitamin D and phosphate	PMT	NOLF

10	Mavrogenis et al, 2010 [15]	S1	42, F	2	Bone pain, paresthesias	Normal	Complete resection	PMTMCT	NOLF

11	Marshall et al, 2010 [16]	T12	55, F	6+	Bone pain; fractures	Hypophosphatemia	Complete resection	PMTMCT	DNMI

12	Akhter et al, 2011 [17]	C5	52, M	1	Fracture	Hypophosphatemia	Complete resection, supplementation of vitamin D, and phosphate	PMTMCT	NOLF

13	Gandhi et al, 2012 [18]	L4	66, F	2,	Bone pain, weakness	Hypophosphatemia, hypocalcemia, low level of vit D3, elevated ALP and PTH	Complete resection	PMTMCT	NOLF

14	Nakamura et al, 2014 [19]	C5	72, M	2.5	Weakness	Hypophosphatemia, elevated ALP and PTH	Complete resection, supplementation of phosphate and calcitriol.	PMTMCT	NOLF

15	Puthenveetil et al [38]	T12	61, F	7	Musculoskeletal pain, weakness, fractures	Hypophosphatemia, increased ALP	Complete resection, supplementation of calcium and phosphate	PMTMCT	NOLF

16	Present case	T1	60, M	6	Bone pain, weakness, paresthesia	Hypophosphatemia, hypocalcemia, elevated PTH	Complete resection, supplementation of calcitriol	PMT	NOLF


	Year

	1992 (n = 321)	2000 (n = 433)	2008 (n = 607)	Trend

	%	n	%	n	%	n	χ2 (d.f. = 1)	P

No diagnosis specified	39	124	24	102	31	189

 Bad news	76	94	73	74	48	91	26.653	< 0.001

 Understanding mental illness	6	8	14	14	24	45	17.096	< 0.001

 Services and advocacy	18	22	14	14	28	53	5.692	0.017

Depression	28	91	34	149	37	226

 Bad news	38	35	32	47	28	63	3.287	0.070

 Understanding mental illness	46	42	59	88	63	142	6.643	0.010

 Services and advocacy	15	14	9	14	9	21	1.976	0.160

Eating disorders	14	45	13	58	14	82

 Bad news	58	26	16	9	17	14	20.297	< 0.001

 Understanding mental illness	42	19	78	45	78	64	14.682	< 0.001

 Services and advocacy	0	0	7	4	5	4	-	-

Anxiety disorders	10	32	14	62	11	67

 Bad news	19	6	21	13	18	12	0.38	0.845

 Understanding mental illness	63	20	69	43	72	48	0.760	0.383

 Services and advocacy	19	6	10	6	10	7	-	-

Schizophrenia	12	38	14	59	9	57

 Bad news	58	22	49	29	68	39	1.535	0.215

 Understanding mental illness	16	6	27	16	25	14	0.758	0.384

 Services and advocacy	26	10	24	14	7	4	6.443	0.011

Bipolar disorder	4	12	3	11	3	19

 Bad news	50	6	64	7	21	4	-	-

 Understanding mental illness	33	4	9	1	53	10	-	-

 Services and advocacy	17	2	27	3	26	5	-	-

Personality disorders	2	7	6	26	1	9

 Bad news	86	6	85	22	56	5	-	-

 Understanding mental illness	0	0	8	2	33	3	-	-

 Services and advocacy	14	1	8	2	11	1	-	-

ADHD	0	0	4	18	4	24

 Bad news	0	0	22	4	8	2	-	-

 Understanding mental illness	0	0	72	13	88	21	-	-

 Services and advocacy	0	0	6	1	4	1	-	-

Other disorders	1	2	1	5	1	7

 Bad news	50	1	40	2	14	1	-	-

 Understanding mental illness	0	0	60	3	71	5	-	-

 Services and advocacy	50	1	0	0	14	1	-	-


Method of risk assessment	Definition	Advantages	Limitations

Clinical prediction rules	The use of a scoring system based on patient- or procedure-related risk factors to quantify risk	Often cost-neutral	Estimates population risk for patient rather than providing an individualized risk assessment

 	 	Requires no specialist knowledge[34]

ASA-PS	Six-point scale used to grade patient according to comorbidities[35]	Validated in a number of settings[36-38]	Inter-observer variability[39]

 	 	 	Poor sensitivity and specificity for prediction of morbidity and mortality on an individual patient basis[33,40]

Lee Revised Cardiac Risk Index (RCRI)	Scores patients according to six variables, including whether the surgery is high risk	Discriminates moderately well between patients at low versus high risk for cardiac events after mixed noncardiac surgery[42]	Designed to identify patients at risk of cardiac complications so may miss patients at risk of other complications who may benefit from PACU care

 	Assesses cardiac risk[41]	Well validated

POSSUM	A more detailed scoring system with 18 components, 6 operative variables and 12 physiological variables[46]	A revision of POSSUM, the Portsmouth POSSUM[43] has been shown to be a better predictor of outcome in certain surgical settings[33,44,45]	Some variables cannot be ascertained until after surgery, making it of limited use for preoperative identification of patients who may benefit from PACU care

 	 	Variations in the model have been devised for specific patient groups, such as the Cr-POSSUM (colorectal), which has been shown to be a better predictor of outcome in this type of surgery[47]

Cardiopulmonary exercise testing	CPET is an integrative and quantitative measure of a patient’s cardiopulmonary reserve	Good evidence that CPET is useful to help predict perioperative morbidity and mortality and may aid triage to an appropriate level of postoperative care[48-50]	In 2008, 17% of Hospital Trusts in England had a CPET service, and a further 7% were in the process of setting one up[52]

The assessment requires the patient to exercise (usually on a cycle ergometer) while oxygen consumption, carbon dioxide production, and other cardiorespiratory variables are measured	RCT in progress to further evaluate its use to stratify to appropriate level of postoperative care[51]


Polymorphism	Reference allele homozygote	Heterozygote	Variant allele homozygote

PAI-2 (SERPINB, rs6095)

Event Rate (%)	34.7	14.6	6.7

Number of patients	72	48	15

Number of patients (%)	53.3	35.6	11.1

LRP-1 (LRP1, rs1800156)

Event Rate (%)	21.1	24.5	33.3

Number of patients	57	53	18

Number of patients (%)	44.5	41.4	14.1

p22phox (CYBA, rs4673)*

Event Rate (%)	36.9	15.1	8.0

Number of patients	65	53	25

Number of patients (%)	45.5	37.1	17.5

TSP-4 (THBS4, rs1866389)*

Event Rate (%)	17.9	36.6	50.0

Number of patients	95	41	4

Number of patients (%)	67.9	29.3	2.9

CETP (CETP, rs708272)*

Event Rate (%)	14.9	26.4	33.3

Number of patients	47	72	24

Number of patients (%)	32.9	50.4	16.8


Group	Location	Gender	Age range (years)	Number of participants

One	ROI	Female	20-29	8

Two	ROI	Female	30-40	9

Three	ROI	Male	29-39	8

Four	NI	Male	29-59	6

Five*	NI	Male	20-25	7

Six	NI	Female	21-59	4

Seven	NI	Male	19-24	8

Eight†	NI	Female	39-45	4

Nine	NI	Female	22-63	5

Ten‡	NI	Female	35-64	7


Gene/Gene Cluster Name	Localization within the POC9 Draft Genome Sequence(GenBank acc. no.)	Protein	Best BLAST Hits:[% Identity] Organism(GeneBank acc. no.)	Predicted Antimicrobial Resistance Profile	Tested Antibiotics	Profile

gcvA-blaOCH	contig00009 (QGST01000009.1)coordinates: 164,062–165,431	class Cbeta-lactamase	[98%] Ochrobactrum tritici C8846-N36 (SME85995)	penams, penems,cephalosporins, cephamycins, monobactams	AMPCFMCTXCRO	RRRR

transcriptional regulator GcvA	[98%] Ochrobactrum anthropi (WP_061347328)

acrAB-TolC	contig00001 (QGST01000001.1)coordinates: 191,438-196,605	transcriptional regulator TetR	[93%] Ochrobactrum oryzae (WP_104756164)	tetracyclines, cephalosporins penams, phenicols, ryfamycins, fluoroquinolones	AMPCIPCFMCTXCROTEMXFRIF	RSRRRSSR

efflux RND transporter periplasmic adaptor subunit	[98%] Ochrobactrum anthropi (WP_061344971)

efflux RND transporter permease subunit	[99%] Ochrobactrum anthropi (WP_061344972)

acrAB-TolC	contig00010 (QGST01000010.1)coordinates: 49,666–54,163	efflux RND transporter periplasmic adaptor unit	[98%] Ochrobactrum sp. (WP_024900215)

efflux RND transporter permease subunit	[99%] Ochrobactrum oryzae (WP_104755654)

qacH	contig00007 (QGST01000007.1)coordinates: 192,104–191,772	efflux SMR transporter	[100%] Ochrobactrum sp. (WP_010661279)	fluoroquinolones	CIPMXF	SS

cmlA/floR	contig00016 (QGST01000016.1)coordinates: 56,907–55,714	CmlA/floR chloramphenicol efflux MFS transporter	[94%] Ochrobactrum anthropi(WP_061345584)	chloramphenicol	C	R

acc (6’)	contig00016 (QGST01000016.1)coordinates: 92,931–92,485	aminoglycoside 6’-acetyl-transferase	[93%] Ochrobactrum anthropi FRAF13(KXO77791)	aminoglycosides	CN	S

tetG-tetR	contig00014 (QGST01000014.1)coordinates: 7148–9063	Tet(A/B/C) family MFS transporter	[87%] Ochrobactrum oryzae(WP_104755825)	tetracyclines	TE	S

transcriptional regulator tetR	[89%] Ochrobactrum oryzae(WP_104755986)


	Fixed effects model	Growth curve model 1	Growth curve model 2

Fixed part

 Intercept	0.820 (0.756 to 0.884)	0.823 (0.779 to 0.866)	0.830 (0.791 to 0.87)

 Age-centred (linear term)	−0.008 (−0.01 to –0.007)	−0.007 (−0.008 to –0.006)	−0.006 (−0.007 to –0.004)

 Age (quadratic term)	−0.0003 (−0.0004 to –0.0003)	−0.0002 (−0.0002 to –0.0001)	−0.0002 (−0.0002 to –0.0002)

 p, 2df	<0.001	<0.001	<0.001

 Frequency of public transport use(ref: every day or nearly every day)

 Two or three times a week	−0.012 (−0.024 to 0.0001)	−0.006 (−0.016 to 0.003)	−0.005 (−0.018 to 0.008)

 Once a week	−0.020 (−0.034 to –0.005)	−0.011 (−0.022 to –0.0002)	−0.006 (−0.019 to 0.008)

 No use: no need	−0.018 (−0.032 to –0.003)	−0.011 (−0.022 to –0.001)	−0.005 (−0.018 to 0.008)

 No use: health problems	−0.058 (−0.075 to –0.040)	−0.090 (−0.104 to –0.077)	−0.115 (−0.135 to –0.095)

 No use: structural reasons	−0.020 (−0.035 to –0.006)	−0.009 (−0.019 to 0.002)	−0.002 (−0.014 to 0.011)

 p, 5df		<0.001	<0.001

 Interaction between age (linear term) and frequency of public transport use

 Age* two or three times a week			−0.0003 (−0.002 to 0.001)

 Age* once a week			−0.001 (−0.002 to 0.0004)

 Age* no use: no need			−0.001 (−0.002 to –0.00002)

 Age* no use: health problems			0.002 (0.0001 to 0.003)

 Age* no use: structural reasons			−0.001 (−0.003 to –0.0002)

 p, 5df			<0.001

Random part

 Level 2 (individual)

 Intercept variance		0.0238	0.0238

 Age-centred (linear term) variance	0.00002	0.00002

 Covariance of intercept and age centred	−0.0004	−0.0004

 Level 1 (wave)

 Intercept		0.020	0.020

 N observations (level 1)	27 509	27 509	27 509

 N clusters (level 2)	9656	9656	9656

 Goodness of fit	Adj R-sq: 0.7273	Deviance: −13 719.59	Deviance: −13 746.54


	Month 1	Month 16	Month 21	Total samplen = 72

Decisions to be made, n (%)

Medical admission or treatment	17 (81)a	12 (44)a	8 (33)a	37 (51)

Psychiatric admission or treatment	5 (24)	13 (48)	13 (54)	31 (43)

Agreement status, n (%)

Agreeing	5 (24)	15 (56)	12 (50)	32 (44)

Not agreeing(or unable to express a choice/not documented)	16 (76)	12 (44)	12 (50)	40 (56)


Food composition of major foods in Uganda (per 100 g of edible portion)

Food	Calories	Protein (g)	Iron (Mg)

Finger millet	346	8.7	4.0

Sorghum	354	10.2	4.1

Ground nuts	577	27.1	2.5

Cowpeas	330	22.4	5.0

Bananas	100	1.5	0.4

Cassava	350	1.8	2.0

Maize	354	9.0	2.5

Beans	330	19.5	8.0

Simsim	593	20.1	9.8

Sweet Potato	166	1.3	1.2

Per capita of protein and calories derived from the major foods

Food	Protein	Calories

	Teso	Uganda	Teso	Uganda

Finger millet	53.40	8.46	2292	497

Sorghum	22.0	5.13	704	164

Ground nuts	27.20	6.03	571	126

Cowpeas	38.00	3.51	570	53

Bananas	0.30	3.24	26	324

Cassava	3.70	3.96	814	854

Maize	7.10	7.21	258	261

Beans	3.90	12.25	55	172

Simsim	3.30	1.53	99	46

Sweet Potato	4.80	2.70	365	205

Others	0	1.83	708	123

Total	163.70	55.85	6462	2825


Cluster #	Expression level

High	Medium high	Medium	Medium low	Low

1	Ribosome	Lumen	Lumen	Lumen	DNA repair/Stress response

2	Oxidative Phosphorylation	Cytoskeleton	Chromosome structure	Zinc finger PHD	Zinc/ion binding

3	Ubiquitination	Protein catabolism	Protein complexes	Transcriptional regulation	Protein catabolism

4	Spliceosome	Chromosome structure	Mitochondrial subunits	Mitochondrial matrix	Protein transport

5	RNA binding	Nucleic acid binding	Nucleic acid binding/Phospho-rylation	Ankyrin repeats	tRNA aminoacylation

6	Electron transport	Ubiquitination	Endoplasmic reticulum	Protein/nucleotide interactions	Zinc finger CH2

7	Protein localization	Protein complex synthesis	Cell cycle	Microtubules	Cell death

8	Protein biosynthesis	Cell cycle	Cellular membranes	Mitochondrial membranes	DNA repair/Polymerase

9	Ribosomal subunits	Mitochondrial components	Ankyrin repeats	Phosphorylation	Suppression of differentiation

10	Protein folding	RNA splicing	tRNA	Zinc finger CH2	Nucleic acid binding


Primary reference, Study, Country (secondary references)	Objectives	Design	Sample size	Patient population	Follow-up

Treatment-related observational studies

Driessen 2008[68], Radboud University Registry, The Netherlands (Driessen 2009[69])	Efficacy and tolerability of etenercept and efalizumab	Registry	118	Psoriasis	24 weeks

Fortune 2003[6], PUVA Study, UK and Ireland	Role of psychological distress on PUVA treatment outcomes	Cohort	112	Plaque psoriasis (chronic)	2 years

Lecha 2005[70], Spanish tacalcitol ointment study	Efficacy and tolerability of tacalcitol	Cohort	556	Psoriasis (moderate)	2 months

Naldi 2008[71], Psocare, Italy	Effect of BMI on clinical response to systemic treatment	Cohort	2368	Plaque psoriasis	3 years

Paul 2003[72] Cyclosporine study, Europe and Canada	Incidence of malignancies in cyclosporine treated patients	Cohort	1252	psoriasis - severe	5 years

Wahl 2005[73], Climate therapy study, Norway	Effectiveness of climate therapy	Cohort	286	Psoriasis	8 months

Heiberg 2008[74], Norwegian register of disease modifying anti-rheumatic drugs, (Heiberg 2007[75])	Comparative effectiveness of TNF inhibitors vs. methotrexate monotherapy	Registry	526	Psoriatic arthritis	1 year

Kristensen 2008[76], South Swedish Arthritis Treatment Group register, (Gulfe 2009[77], Geborek 2002[78], Kristensen 2006[79])	Efficacy, utility and tolerability of TNF-inhibitors (etanercept, infliximab, adalimumab)	Registry	261	Psoriatic arthritis	7 years

Sparado 1997[80], Cyclosporin Study, Italy	Probability of continuing to take cyclosporine vs. other DMARDS	Cohort	172	Psoriatic arthritis	10 years

Saad 2009[81], British Society for Rheumatology Biologics Register, (Harrison 2009[82], Silman 2003[83])	Effectiveness and tolerability of TNF-inhibitors (etanercept, infliximab, adalimumab)	Registry	566	RA, psoriasis, psoriatic arthritis	1 year

Non-treatment related observational studies

Carrascosa 2006[84], EPIDERMA cost of illness, Spain	Direct and indirect cost; relationship between cost and severity	Cohort	797	Psoriasis	1 year

Colombo 2008[11], Cost of illness, Italy	Direct and indirect cost; HRQOL; relationship between cost, HRQOL and severity	Cohort	150	Moderate to severe plaque psoriasis	3 months

Schmid-ott 2005[85], Bad Bentheim Rehabilitation Hospital, Germany	Relationship between the degree of stigmatisation and gender, skin symptoms, PASI and SPASI	Cohort	166	Psoriasis	1 year

Ali 2007[86], Husted 2007[2], Gladman 2009[16], Rohekar 2008[87], Toronto PsA clinic, Canada, (Chandran 2007[88], Gladman 1995[89], Gladman 1998[90], Gladman 1999 [91], Gladman 2001[92], Husted 2005[93], Wong 1997[94])	(1) Mortality associated with PsA; (2) relationship between physical functioning, disease activity and joint damage; (3) CVD associated with PsA; (4) malignancies associated with PsA	Cohort	382 to 680	Psoriatic arthritis	26 years

Kane 2003[95], St. Vincent's University study, Ireland, (Kane 2003a[96])	Clinical presentation, outcome and prognosis of early PsA	Cohort	129	Early psoriatic arthritis	2 years

Lindqvist 2008[97], SwePsA registry, Sweden, (Svensson 2002[98])	Factors associated with disease progression; outcome of treated and non-treated groups, comparison of outcomes with RA patients	Registry	135	Early psoriatic arthritis	2 years


Symbol	Name	Function	Reference

PLK1	polo-like kinase 1	cell cycle regulation	[13-19]

CDK16	cyclin-dependent kinase 16	cell cycle regulation	[20]

RYK	receptor-like tyrosine kinase	cellular growth and differentiation Regulation	[21]

MTOR	mechanistic target of rapamycin (serine/threonine kinase)	cellular metabolism, growth, and proliferation Regulation	[22-24]

STK17B	serine/threonine kinase 17b	positive regulation of apoptosis	[25]

PLK4	polo-like kinase 4	cell cycle regulation	[17,26]

MAST2	microtubule associated serine/threonine kinase 2	cellular growth and differentiation Regulation	[27]

MAP3K4	mitogen-activated protein kinase kinase kinase 4	role in signal transduction cascades	[28]

MARK2	MAP/microtubule affinity-regulating kinase 2	cell polarity and microtubule dynamics regulation	[29]

CDK1	cyclin-dependent kinase 1	cell cycle regulation	[13,15-17,30,31]

NEK2	NIMA (never in mitosis gene a)-related kinase 2	cell cycle regulation	[14-16,30]

PRKCSH	protein kinase C substrate 80K-H	roles in inflammation, cell growth, signaling and death	[32]

AURKA	aurora kinase A	cell cycle regulation	[33,34]

BUB1	mitotic checkpoint serine/threonine kinase	cell cycle regulation	[35]

CDC7	cell division cycle 7 homolog (S. cerevisiae)	cell cycle regulation	[30]

SRPK1	SRSF protein kinase 1	cellular growth and differentiation Regulation	[36]

TTK	TTK protein kinase	cell cycle regulation	[14-16,37,38]

VRK1	vaccinia related kinase 1	cell cycle regulation	[39,40]


 	D-dimer ≥10 μg/mL after treatment

 	No	Yes	p∗

 	(n = 31)	(n = 21)

Male sex	18 (58.1%)	10 (47.6%)	0.458

Age, years	63 (55–71)	63 (55–70)	0.970

DWI patterns	 	 	0.724

 Single vascular territory	6 (19.4%)	3 (14.3%)

Single lesion	3	2

Multiple lesions	3	1

 Multiple vascular territories	25 (80.6%)	18 (85.7%)

Treatment	 	 	0.002

 Enoxaparin	21 (67.7%)	5 (23.8%)

 Warfarin	10 (32.3%)	16 (72.6%)

Cancer profiles

 Primary cancer type	 	 	0.586

Lung	15 (48.4%)	12 (57.1%)

Gastrointestinal	4 (12.9%)	3 (14.3%)

Hepatobiliary	5 (16.1%)	5 (23.8%)

Breast-gynecologic	4 (12.9%)	1 (4.8%)

Other	3 (9.7%)	0 (0%)

 Systemic metastasis	23 (74.2%)	20 (95.2%)	0.067

 Adenocarcinoma	19 (61.3%)	17 (85.0%)	0.070


Generic name	Study drug name (Brand name)	Active ingredient content	Manufacturers/distributors

amlodipine besilate	Amlodin® tablets 2.5	containing 2.5 mg of amlodipine	Sumitomo Pharmaceuticals Co., Ltd.

	Amlodin® tablets 5	containing 5 mg of amlodipine

	Norvasc® tablets 2.5 mg	containing 2.5 mg of amlodipine	Pfizer Japan Inc.

	Norvasc® tablets 5 mg	containing 5 mg of amlodipine


BPG	Patient Eligibility Criteria 	Participating Program Units

Asthma	Patients who present to the participating units with a primary or secondary diagnosis of asthma	Emergency, in-patient and medical units

Breastfeeding	Postpartum women and their infants with a singleton birth, gestational age of 37 or more weeks, hospital length of stay for mother and infant 24 hours or more after birth, infant not delivered by a midwife. Additional infant criteria included: no major congenital anomalies, no galactasemia. Additional postpartum women criteria included: no documented use of street drugs, no major psychiatric illness, baby not up for adoption.	Labour and delivery, postpartum, neonatal intensive care, and public health unit

Delirium-Dementia-Depression	Clients admitted to participating units, age 65 years and older.	Surgical, medical and rehabilitation units

Smoking Cessation	Clients age 18 years and older admitted to participating unit. For outpatients, admission to out-patient services within the past month and currently attending the clinic.	In-patient and out-patient long-term mental health, in-patient unit for drug and alcohol addition, in-patient unit for acute psychiatric disorders, resource unit for nicotine dependency

Venous Leg Ulcers	All clients with new and recurrent venous leg ulcers. Patients with primary lymphedema, vasculitis, and under diabetic management excluded.	Chronic care unit, wound care clinic, and community care agency

Diabetes	Adults age 18 and over with a diagnosis of diabetes admitted to one of the participating units. Women with gestational diabetes excluded.	Oncology, medical and diabetes care and education centre and community care agency


Organism	Precision	Recall	F-score

Mouse	0.77	0.81	0.79

Yeast	0.97	0.84	0.90

Fly	0.83	0.80	0.82

FlyAccept matches of synonyms associated to up to 3 different Entrez Gene entries	0.74	0.83	0.79

Human	0.86	0.81	0.84


Command	Value	Description

ACK	0×06	It is sent when a frame has been received and decoded correctly.

NACK	0×15	It is sent when a frame has not been decoded correctly.

RESET	0×08	It forces the node to be reset. After this command, the node sends an ACK and resets itself. For the next 2 seconds the node enters a programing mode which allows the central computer to reprogram the device.

ALIFE	0×0C	This command is sent to a specific node to check if it is in working mode. If the board is correctly working, it answers with an ACK command.


	N	%	% susceptible TMP/SMX	Ciprofloxacin	Nitrofurantoin

E. coli	73	82	93	100	95

P. mirabillis	5	5.6	100	100	na

K. pneumonia	4	4.4	100	100	50

S. aureus	3	3.3	100	0	100

C. koseri	2	2.2	100	100	100

B-hemolytic Strep	1	1.1	na	na	na

S. saphophyticus	1	1.1	0	100	100

Total	89	100


Dimension	Categories

Primary diagnosis	Organic mental health problem (most commonly dementia)

Depression or anxiety

Other mental health problem e.g., schizophrenia

Main reason for admission	Risk of deliberate self-harm

Other risks i.e., self-neglect, accidental self-harm, abuse/exploitation or falls, or carer stress

Behaviour management related i.e., need for behaviour management, risk of harming others or care breakdown

Need for diagnostic assessment, medication review or treatment

Challenging behaviour	Low (behaviour score 0 or 1)

Medium (behaviour score 2–7, typically including agitation, wandering and/or disturbed sleep)

High (behaviour score 8–14, typically including resistance to care and/or aggression)

Living situation	Resident primary carer (including care home residents)

No resident carer


Adsorbent	qm (mg/g)	Ref.

GO sponge	446	[38]

GO-CS sponge	468	[39]

GO-Fe3O4 sponge	526	[40]

RGO sponge	27	[38]

RGO-MFe2O4	34.72	[41]

RL-GO	529.10	[42]

MCGO	95.16	[43]

GO-biopolymer gel	701.78	[44]

GO-COOH sponge	780 ± 47	This study


Dataset	Note	Reference

Global	289 isolates; Human and environmental isolates, from six countries (Australia, Indonesia, Laos, Singapore, Vietnam, USA), sampled to maximize diversity and exclude members of a clonal outbreak, metadata includes invasiveness, acquisition type and sample site. Invasiveness status of human isolates consists of three types: carriage (isolates not considered to be the cause of an infection), non-invasive (pneumonia, urinary tract infection, wound infection; with no recorded bacteraemia) and invasive (isolated from normally sterile sites: blood, CSF, intra-ocular, pleural, pericardial, joint fluids, deep-seated tissue abscesses). Acquisition type is either community acquisition (isolated within 48 hours of admission to hospital) or hospital acquisition (isolated after 48 hours after admission)	(Holt et al. 2015)

UK Hospital	162 isolates; Collection from Cambridge University Hospitals NHS Foundation Trust in the UK over a period of seven years, invasive isolates isolated from normally sterile sites. Biased selection for antimicrobial resistance to three or more of six antimicrobial classes (penicillins, amoxacillin-clavulanate, aminoglycosides, fluoroquinolones, trimethoprim and third-generation cephalosporins), metadata includes sample site	(Ellington 2016)

Nepal Hospital	88 isolates; Nepalese hospital outbreak from May to December 2012, consisting mainly of two clonal lineages; randomly selected blood cultures.	(Chung The et al. 2015)

Preantibiotic	34 isolates; Collection of isolates isolated before the widespread use of antibiotics (pre 1949). No additional metadata available.	(Wand et al. 2015)


Standard sections	Keywords

Introduction	Introduction, Background, Review, Context, Literature

Materials and Methods	Methods, Materials, Implementation, Experimental

Results	Results, Findings

Discussion	Discussion

Conclusion	Conclusion(s)


	Patients

Characteristic	No.	%

Median age at onset (yr)	4 (0.1-15.7)

Gender

 Female	74	81

 Male	17	19

JIA onset subtype

 Oligoarticular	62	68

 Polyarticular	29	32

NSAID*

 Naproxen	87	95

 Meloxicam	4	4

 Tolmetin	11	12

 Ibuprofen	16	18

 Rofecoxib	6	7

 Diclofenac	8	9

 Celecoxib	3	3

 Nabumetone	2	2

Other Medications†	6	7

Median duration of treatment (yr)

 Oligoarticular	1.5 (0.14-17.7)

 Polyarticular	0.58 (0.11-9.8)


No	Pathotype	AGE	N 9-p	N 10-p	N 14-p	Micro	Sexta

 1	EAggEC	P

 2	EAggEC	P			L	L

 3	EAggEC	P				L

 4	EAggEC	P	L	L	L	L	L

 5	EAggEC	P			L		L

 6	EAggEC		L	L	L	L

 7	EAggEC	P		L	L	L	L

 8	EAggEC	P			L	L

 9	EAggEC	P		L	L	L

10	EAggEC	P		L	L	L	L

11	EIEC		L	L	L	L	L

12	EIEC		L	L	L	L	L

13	EIEC		L	L	L	L	L

14	EPEC

15	EPEC			L	L

16	EPEC

17	EPEC

18	EPEC		L	L	L

19	EPEC	P		L	L	L	L

20	EPEC	P

21	EPEC	P

22	EPEC	P	L	L	L

23	EPEC	P				L

24	EPEC					L	L

25	EPEC			L	L

26	EPEC				L		L

27	EPEC	P

28	EPEC	P		L	L		L

29	VTEC		L	L	L	L	L

30	VTEC		L	L	L	L	L

31	VTEC		L	L	L	L

32	ETEC O114	P		L	L	L

33	ETEC O167	P				L	L

34	ETEC O6	P			L

35	ETEC O25	P		L	L

36	ETEC O25	P

37	ETEC O78	P		L	L	L	L

38	ETEC O115	P		L	L

39	ETEC O114	P

40	ETEC O115	P				L	L

41	ETEC O25	P				L

42	ETEC O115	P

43	ETEC O6	P	L	L	L

44	ETEC O167	P

45	ETEC O114	P		L	L	L

46	ETEC O8	P


Factor	Level	n	Test +ve	%	OR	95 % CI	χ2	P value

Farm type	Extensive	33	14	42.4

Intensive	4	3	75	4.07	0.38–43.38	1.52	0.22


Line	Patients by gender identity	Number (a)

20	Male

21	Female

22	Transgender male/female-to-male

23	Transgender female/male-to-female

24	Other

25	Choose not to disclose

26	Total patients (sum lines 20 to 25)


Patients	n = 13

Mean age years (min – max)	53 (28–77)

Male/female	7/6

Mean height cm (min-max)	166 (146–177)

Mean weight kg (min-max)	72 (44–105)

Mean BMI (min-max)	27 (19–38)

ASA I/II/III/IV	2/4/2/5

Mallampati class I/II/III/IV	6/2/2/3

Orally/nasally awake fiberoptic intubation	6/7

Reasons for awake fiberoptic intubation

 o Cervical spine disease, i.e. rheumatoid arthritis	5

 o Head and neck abnormality, i.e. supraglottic cancer, oral abscess	2

 o Thyroidea abnormality	3

 o Upper airway trauma, i.e. acute pharyngeal bleeding, mandible fracture	3

Previous experience with anaesthesia, yes/no	10/3


Genome	Proteome size	Clustered proteins	Core proteome

Halobacterium sp. NRC-1	2626	2174 (82.8%)	857 (32.6%)

Haloarcula marismortui 	4240	3464 (81.7%)	893 (23.1%)

Natronomonas pharaonis 	2822	2285 (81.0%)	847 (30.0%)

Haloquadratum walsbyi 	2626	2108 (80.3%)	835 (31.8%)

Halorubrum lacusprofundi 	3913	3166 (80.9%)	870 (22.2%)

Halogeometricum borinquense 	4303	3209 (74.6%)	891 (20.7%)

Halomicrobium mukohataei 	3548	2902 (81.8%)	858 (24.2%)

Halorhabdus utahensis 	3160	2334 (73.9%)	856 (27.1%)

Haloferax volcanii 	4074	3240 (79.5%)	870 (21.4%)


Strains	Characteristics	Source/origin

J940047	Wild-type isolate	Clinical, Portugal

J940557	Wild-type isolate	Clinical, Portugal

J940915	Wild-type isolate	Clinical, Portugal

06L3FF02	Wild-type isolate	Wine cellar; Bairrada Wine Region, Portugal

06L1FF11	Wild-type isolate	Wine cellar; Bairrada Wine Region, Portugal

06L3FF15	Wild-type isolate	Wine cellar; Bairrada Wine Region, Portugal

06L6FF20	Wild-type isolate	Wine cellar; Bairrada Wine Region, Portugal

UM218	Wild-type isolate	Vineyard; Vinho Verde Wine Region, Portugal

UM237	Wild-type isolate	Vineyard; Vinho Verde Wine Region, Portugal

BB1235	Wild-type isolate	Vineyard; Bairrada Wine Region, Portugal

BB2453	Wild-type isolate	Vineyard; Bairrada Wine Region, Portugal

Lalvin EC-1118	Commercial; used in the Vinho Verde Wine Region	Champagne, France

Lalvin ICV D254	Commercial; used in the Bairrada Wine Region	Rhône Valley, France

IOC 18–2007	Commercial; used in the Bairrada Wine Region	Institut Oenologique de Champagne, France

AEB Fermol Rouge	Commercial; used in the Bairrada Wine Region	Montpellier University, France

Davis Lalvin 522	Commercial; used in the Bairrada Wine Region	University of California, Davis, USA

S288C	MATα SUC2 mal mel gal2 CUP1 flo1 flo8-1	Mortimer & Johnston, 1986 [87]


Gene	Accession number	Forward Primer (5'-3')	Reverse Primer (5'-3')	qPCR primer combination (product length)	Sequencing primer combination (product length)

GST mu 1	AF462190	F1: GCTATTGGGATCTTCGTGGA	R1:TGCCCAAATACCGGAGAATA	F1/R1 (228 bp)	F1/R2 (628 bp)

			R2: TGTATTCCATTTCGCCATTG

GST mu 2	AY825933	F1: GCCCATCAGAATGATGCTTT	R1: TTCTCAAGATAATCTGGCTTTA	F1/R1 (344 bp)	F1/R2 (519 bp)

			R2: GAATCGATTAACATAGTTGCC

GST mu 3	AY825934	F1: ATCTGGCGTGCAGATAAAC	R1: CTCGAGCCTTCTCGAAATTG	F1/R1 (241 bp)	F2/R2 (929 bp)

		F2: ACGCAGTTTTGTTTCGTTGG	R2: GTCTGGATTTGTTCCGTGGT

GST delta 1	AY825935	F1: TGGACCAACATTAGCCGATA	R1: TTGCATTTGTTGAGCGAATC	F1/R1 (193 bp)	F2/R1 (631 bp)

		F2: CAGAAAGTGCACCATGTCGT

GST delta 2	AY825936	F1: AGCTCAAACCGATGAGCCTA	R1:GCGAATGCAATGATGTTAGC	F1/R1 (192 bp)	F2/R1 (652 bp)

		F2:TGGGTTCTATTCGACCGATAA

GST delta 3	AY825937	F1: ATGGAGGTGGTTTGAACGAG	R1: TCGTGATCGACAGCATTCAT	F1/R1 (244 bp)	F2/R1 (580 bp)

		F2: AGAGAGCCCACCATGTCGTA

P-glycoprotein	DQ146410	AGGCAACTTCAGCACTCGAT	ACATTCTGACCGCCATCAAT	155 bp

SsCl	EF611372	TGATTTCTATATGTCGGGCCATTTG	CAGGGAACCAAAGATCAACA	329 bp

β-actin	EU624346	CAACCATCCTTCTTGGGTATG	CCAGCTTCGTCGTATTCTTGT	311 bp


Characteristics	HR	95% CI	P-value

Health knowledgea

 Low (0)	1

 Moderate (1–3)	0.63	0.33–1.19	0.15

 High (4–15)	0.43	0.22–0.86	0.02

Age	1.04	1.00–1.07	0.04

Sex	0.81	0.42–1.58	0.54

Smoking status

 Never	1

 Current	2.24	1.13–4.44	0.02

 Former	0.92	0.25–3.34	0.90

Comorbidities

 Hypertension

No	1

Yes	0.96	0.50–1.85	0.91

 Hyperlipidemia

No	1

Yes	1.88	1.00–3.55	0.05

 Atrial fibrillation

No	1

Yes	3.61	1.28–10.20	0.02

 Coronary artery disease

No	1

Yes	1.16	0.67–2.01	0.60

 Congestive heart failure

No	1

Yes	1.61	0.75–3.45	0.22


	Different scales	Mean	SD	Score ≥ 3,5 (total)

Images of God (5 point scale)	Personal God	2,75	1,42	18 (50)

Non-personal God	2,70	0,75	24 (49)

Unknowable God	3,23	1,18	19 (46)

Attitudes towards death (5 point scale)	Explicitly religious	2,53	1,34

Agnostic/Atheistic	3,35	0,96

Reincarnation	2,17	1,08

Community	2,43	1,24

Continuation	2,70	1,27

Spiritual wellbeing scales (4 point scale)	Existential wellbeing	2,96	,59

Relation to Self	3,05	,54

Relation to Others	3,30	,50

Relation to Something Greater	2,40	,73

Relation to God (1-item scale for ‘believers’ n = 29 completed this scale)	2,38	1,02


Pt.	Indication for tons.	CP type	Initial cleft repair	Protons. endoscopy	Posttons. endoscopy	Speech intelligibility	VPI Severity

Preop.	postop.	Diff.	Preop.	Postop.	Diff.

4	VPI	SM	Unk.	Palate 9 lat 4	Palate 9 lat 4	2	2	0	2	2	0

5	VPI	None	None	Palate 7 lat 2	Palate 9 lat 4	2	2	0	3	2	−1

6	VPI	UC	2 flap	Palate 0 lat 0	Palate 0 lat 1	3	2	−1	2	2	0

7	VPI	UC	2 flap	Palate 9 lat 2	Palate 9 lat 1	3	2	−1	1	2	1

9	VPI	UC	2 flap	Palate 1 lat 1	Palate 2 lat 1	3	4	1	4	4	0

12	VPI	UC	2 flap	Palate 5 lat 1	Palate 5 lat 3	4	4	0	4	4	0

15	Recurrent strep + VPI	I	2 flap	Palate 8 lat 4	Palate 9 lat 4	2	1	−1	1	2	1

16	VPI	None	None	Palate 9 lat 4	Palate 7/8, lat 1	3	3	0	3	3	0

17	OSA	UC	2 flap	Palate 8 lat 0	Palate 8 lat 1	2	2	0	2	2	0

22	VPI	SM	furlow	Palate 4 lat 0	Palate 3.5 lat 1	4	4	0	3	3	0


Genes	Primer Sequences (5'-3')	Cycles	Size (bp)	Annealing Temperature (°C)

Pluripotency-associated markers

Oct4	F	TCTCGCCCCCTCCAGGT	30	218	53

	R	GCCCCACTCCAACCTGG

Sox2	F	GGCAGCTACAGCATGATGCAGGACC	34	130	60

	R	CTGGTCATGGAGTTGTACTGCAGG

Endodermal-associated markers

FoxA2	F	GGGAGCGGTGAAGATGGA	38	89	55

	R	TCATGTTGCTCACGGAGGAGTA

Gata6	F	GAGTGAGAGAAGATGGAAGGG	38	250	55

	R	CGCACATGAAATCTGGATGTGG

Ectodermal-associated markers

Nestin	F	CAGCTGGCGCACCTCAAGATG	30	209	55

	R	AGGGAAGTTGGGCTCAGGACTGG

Pax6	F	AACAGACACAGCCCTCACAAACA	30	275	55

	R	CGGGAACTTGAACTGGAACTGAC

Mesodermal-associated markers

Brachyury	F	GAACCAGCACCCTGTGTCCAC	38	608	57

	R	GCCACGACAAAAAGTCACTGC

Goosecoid	F	CTCAACCAGCTGCACTGTC	38	322	55

	R	GTCAGCTGTCCGAGTCCAAATC

Control-associated markers

GAPDH	F	ATGGAGAAGGCTGGGGCTC	28	196	55

	R	AAGTTGTCATGGATGACCTTG


Referrals & Services	Team 1	Team 2	Team 3	Team 4	Team 5

	T1	A2	T	A	T	A	T	A	T	A

# of referrals	1104	61	0	0	172	10	2742	152	250	14

# of new registration	418	23	1163	65	81	5	488	27	71	4

# of consultation	1889	105	7207	400	107	6	2682	149	110	6

# of telephone contact with Patient	328	18	2296	128	76	4	585	33	50	3

# of telephone contact with family members	0	-	0	-	33	2	43	2	15	1


 Screening options

Fecal screening tests	These tests search for occult blood in stool, which is nonspecific but can be detected especially in larger polyps and CRC. It is important to collect samples from consecutive bowel movements [39, 40].Guaiac fecal occult blood test (gFOBT) detects qualitatively heme in the stool, using a guaiac material to which hydroperoxidase is added. Heme promotes a process that leads to the guaiac's oxygenation and to a blue discoloration [41, 42]. It has a low sensitivity for the detection of CRC, but when performed every year or two, mortality is reduced [39, 43, 44].Fecal immunochemical tests (FITs) use monoclonal or polyclonal antibodies to detect human haemoglobin. They can give qualitative or quantitative results. FIT is more accurate than gFOBT, because it does not react with nonhuman heme and is less sensitive to upper gastrointestinal tract's bleeding [41, 45].

Endoscopic screening	Flexible Sigmoidoscopy is a screening option that allows examining the rectum and the lower part of the colon. It is an invasive technique that requires simple bowel preparation but cannot detect lesion in the whole colon [41, 45].Colonoscopy is esteemed as the gold standard for CRC screening; it allows exploring the whole colon and removing the suspicious lesions [46, 47]. It is an invasive and expensive exam that must be performed if any other test has a positive result [39]. The most common side effect is postpolypectomy bleeding, but also tearing and perforation may be possible [45]. It is recommended that colonoscopy be practiced every 10 years in average-risk patients that underwent to a complete, negative exam [39, 48, 49].

CT-colonography (CTC)	CTC is a noninvasive test that has become a common method for CRC screening. It requires a bowel preparation, but sedation is not needed. The estimated sensitivity and sensibility in detecting polyps > 1 cm are high, above 90%. Limitation of this technique includes low sensitivity for small lesion and serrated polyps, the exposure to radiation, and the need of follow-up for extra colic incidental findings [39, 49–51].


Effect:	Relevancea	Pointsb	Classc

 	 	1	2	3	4	5

1	Temperature: Heat-related mortality	6	2	1	 	 	41	IV

2	Temperature: Heat-related cardiovascular problems	1	 	2	 	 	11	III

3	Temperature: Heat-related respiratory problems	1	1	 	1	 	11	III

4	Temperature: Heat-related stress and sleep disturbance	1	 	 	 	 	5	II

5	Temperature: Cold-related mortality	 	 	 	 	 	 	I

6	Temperature: Cold-related diseases	 	 	 	 	 	 	I

7	Temperature: Drought-related exposure to contaminants	 	 	 	 	 	 	I

8	Temperature: Shortages of drinking water	 	 	 	 	1	1	II

9	Temperature: Dehydration	 	2	 	 	 	8	II

10	Allergies: Asthma	 	 	1	 	1	4	II

11	Allergies: Allergic eczema	 	 	 	 	 	 	I

12	Allergies: Hay fever: duration of pollen season	 	2	 	1	2	12	III

13	Allergies: Hay fever: pollen types, abundance and allergenicity	 	2	1	 	 	11	III

14	Pests: Wasps	 	 	 	 	 	 	I

15	Pests: Oak processionary caterpillar	 	1	 	 	 	4	II

16	Vector-borne: Native vector-borne diseases	1	1	 	 	1	10	II

17	Vector-borne: Incidents of non-native vector-borne diseases	1	2	2	1	 	21	IV

18	Vector-borne: Epidemics of non-native vector-borne diseases	2	 	 	2	 	14	III

19	Food/water-borne: Food poisoning	 	 	 	1	 	2	II

20	Food/water-borne: Legionnaires Disease	 	 	 	 	1	1	II

21	Food/water-borne: Contamination of swimming/recreation water	 	 	 	1	2	4	II

22	Air quality: Respiratory problems due to ground-level ozone	 	 	1	2	 	7	II

23	Air quality: Respiratory problems due to particulate matter	 	 	 	 	 	 	I

24	Air quality: Air quality-related cardiovascular problems	 	 	 	1	1	3	II

25	Flood/storm: Flood-related mortality	1	 	1	1	 	10	II

26	Flood/storm: Flood-related infectious diseases	 	 	 	 	 	 	I

27	Flood/storm: Flood-related exposure to dangerous substances and contaminants	 	 	1	 	 	3	II

28	Flood/storm: Flood-related respiratory problems	 	 	 	 	 	 	I

29	Flood/storm: Flood-related mental health problems	 	1	 	 	2	6	II

30	Flood/storm: Storm-related mortality and injury	 	 	 	 	 	 	I

31	UV: Cataract	 	 	 	 	 	 	I

32	UV: Skin cancer	 	 	2	 	 	6	II

33	UV: Weakening of the immune system	 	 	 	 	 	 	I

34	OTHER: societal disruption elsewhere	1	 	 	 	 	5	II


Parameters	Supplemented group (n = 9)	Control group (n = 7)

Age (years)	21.3 ± 0.82	21.3 ± 0.71

Body mass (kg)	93.6 ± 6.02	81.6 ± 9.44

Body height (cm)	192.6 ± 6.53	189.0 ± 4.62

Duration of training (years)	7.5 ± 1.5	6.9 ± 1.2


Strain	Phenotypeb	Vancomycin MIC (μg/ml) by Etest after various periods of incubation

CLSI classification (48 h)	New classification	Without antibiotics	With mupirocin at 0.032 μg/ml

48 h	72 h	96 h	120 h	144 h	48 h	72 h	96 h	120 h	144 h

209P	VSSA (MSSA)	VSSA (MSSA)	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5

N315ΔIP	VSSA (MRSA)	VSSA (MRSA)	2	2	2	2	2	2	2	2	2	2

Mu3	hVISA	hVISA	3	3	3	3	3	3	3	3	3	3

Mu50	VISA	VISA	12	12	12	12	12	12	12	12	12	12

MI (HIP5827)	VISA	VISA	12	12	12	12	12	12	12	12	12	12

Mu3-6R	VISA	Slow VISA	8	8	12	12	16	16	16	16	16	16

Clinical blood culture isolates from 9 hospitals

MRSA212	VSSA	VSSA	1.5	2	2	2	2	3	3	3	3	3

MRSA84	VSSA	hVISA	2	2	3	3	3	3	3	3	3	3

MRSA220	VSSA	hVISA	1.5	3	3	3	3	3	3	3	3	3

MRSA192	VSSA	hVISA	2	2	2	2	2	2	2	2	2	2

MRSA190	VISA	Slow VISA	4	8	8	8	8	12	12	12	12	12

MRSA194	VISA	Slow VISA	4	6	8	12	12	8	12	12	12	12

T series clinical blood culture isolatesa

T12	VISA	Slow VISA	4	4	8	8	8	8	8	8	8	8

T15	VISA	Slow VISA	4	6	8	8	8	8	8	8	8	8

T61	VISA	Slow VISA	4	6	8	8	8	8	8	8	8	8

T89	VISA	Slow VISA	4	8	16	16	16	16	16	16	16	16

T122	VISA	Slow VISA	4	8	8	8	8	6	6	8	8	8

T123	VISA	Slow VISA	4	6	8	8	8	6	8	8	8	8

T12-L	hVISA	hVISA	3	3	3	3	3	3	3	3	3	3

T15-L	hVISA	hVISA	3	3	3	3	4	4	4	4	4	4

T61-L	hVISA	hVISA	3	3	3	3	4	6	6	6	6	6

T89-L	hVISA	hVISA	3	3	3	3	3	3	3	3	3	3

T122-L	VSSA	VSSA	2	2	2	2	2	3	3	3	3	3

T123-L	VSSA	VSSA	2	2	2	2	2	3	3	3	3	3


	Average annual costs	References

Health care costs (per episode/year)

 Myocardial infarction	$18627	Bergenheim et al., 2012 [12]

 Heart failure	$14118	Bergenheim et al., 2012 [12]

 Stroke	$7939	Bergenheim et al., 2012 [12]

 Hypoglycemia events requiring medical assistance	$199	Bergenheim et al., 2012 [12]

 Severe hypoglycemia event	$146	Bergenheim et al., 2012 [12]

 Weight gain	$289	Bergenheim et al., 2012 [12]

Drug cost (per patient/year)

 Metformin, generic drug	$24	NADAC (January 2015) [22]

 Dipeptidyl peptidase-4 inhibitor, brand	$3500 ($3401; $3599)	NADAC (January 2015) [22]

 Sulfonylurea (glipizide), generic	$16	NADAC (January 2015) [22]

 Insulin glargine, brand	$3646	NADAC (January 2015) [22]


	N=55

Motor score

 Voluntary movement score [0–20]	6.33 (5.71)

 Stiffness [0–8]	2.20 (2.14)

 Chorea [0–16]	5.19 (4.51)

 Precise movement [0–8]	4.06 (2.46)

Behavioural score

 Depression anxiety [0–20]	9.12 (5.01)

 Temper [0–8]	2.81 (2.18)

 Psychotic disorder [0–12]	1.35 (2.16)

 Cognition [0–12]	3.52 (2.97)

Functional score

 Functional score [0–7]	3.06 (2.53)


Characteristic	N

Gender

 Male/female 	33/90

Age

 21 to 30 y	22

 31 to 40 y	36

 41 to 50 y	30

 >50 y	35

Years in practice

 <5 y	19

 5 to 10 y	21

 11 to 20 y	34

 >20 y	49

Average number of clients with nonsurgicalknee osteoarthritis treated per year

 1 to 20	43

 21 to 40	42

 >40	38


Diagnostic miR(s)	Disease Setting	Description	Reference(s)

miR-20a, miR-24, miR-25, miR-145, miR-152, miR-199-5p, miR-221, miR-222, miR-223, miR-320	Lung Cancer	10 microRNAs were found to have significantly different expression levels in NSCLC serum samples compared with the control serum samples.	[24]

miR-10b, miR-155, miR-195, miR34a	Breast Cancer	Increased expression of miR-10b, miR-155, and miR-195 and decreased miR-34a was associated with disease.	[25]

miR-221	Ovarian Cancer, Melanoma, Lymphoma	Increase expression in several different cancers compared to control serum samples.	[27,28,29]

miR-141, miR-16, miR-92a, miR-92b, miR-103, miR-107, miR-197, miR-34b, miR-328, miR-485-3p, miR-486-5p, miR-574-3p, miR-636, miR-640, miR-766, and miR-885-5p.	Prostate	Levels of these microRNAs were found to be higher in the serum of patients compared to controls.	[21,26]


Rank	GAN	[3]	Rank	Gene description

			S2N	SVM-RFE

1	M27891	•	1	2	cystatin C (CST3)

2	M28130	•	25	3	interleukin 8 (IL8)

3	M84526	•	5	1	D component of complement (adipsin) (DF)

4	M19507		131	7	myeloperoxidase (MPO)

5	Y00787	•	23	4	interleukin-8 precursor

6	M11722		71	41	deoxynucleotidyltransferase, terminal (DNTT)

7	X95735	•	2	11	zyxin (ZYX)

8	D88422		3	8	cystatin A (CSTA)

9	M27783		15	5	elastase 2, neutrophil (ELA2)

10	M96326	•	75	10	azurocidin 1 (AZU1)


	SLD (n = 20)	HAD (n = 20)

Body weight (g)

initial	198 ± 4	200 ± 5

1 week	257 ± 6	247 ± 6

6 weeks	450 ± 10	438 ± 10

70 days	525 ± 12	498 ± 12

Food intake (g/kg b.w./day)

1st week	116 ± 4	122 ± 4

6th week	74 ± 1	73 ± 1

last week	64 ± 2	66 ± 1


Group	Description of the group	Strength

TM1	The total number of skills is 2; number of skills of each employee and task is 2.	The quantum of effort needed in every task is to be equal; each employee has the same contribution of maximum dedication and salary.

TM2	The amount of skills is 10; number of employee skills is 5–7; number of skills required in the task is 3-4.	The functionalities in TM2 and TM3 have the same TPG; the tasks have the same efforts; each employee has maximum dedication and salary.

TM3	The amount of skills is 15; number of employee skills is 6-7; number of skills required in the task is 2-3.

TM4	The amount of skills is 10; number of employee skills is 2-3; number of skills required in the task is 4-5.	The functionalities in TM4 and TM5 have the same TPG; the tasks have the same effort and each employee has maximum dedication and salary.

TM5	The amount of skills is 5; number of employee skills is 3-4; number of skills required in the task is 2-3.


Gender	Age (years)	Length of diagnosis of hypothyroidism (years)

Female	93	13

Female	80	10

Male	84	Approx. 8

Female	82	24

Male	83	15

Female	88	9

Female	85	14

Female	80	3

Female	83	14

Female	82	18

Female	85	16


Abbreviated Trial Name/NCT#	Phase	Agent(s)	Study population	Expected Primary Endpoint

NCT01935921	Ib	Cetuximab, ipilimumab and IMRT	stage III-IVaHPV+ OPSCC	Dose limiting toxicities (DLT)

RTOG 3504NCT02764593	III w/phase I lead in	Nivolumab and cisplatin CRT	stage III-IV, intermediate to high risk HNSCC	DLT for phase I

NCT02777385	II	Concurrent vs sequential pembro, cisplatin and IMRT	stage III-IVbHNSCC	1 year PFS1 year failure rateAcute toxicity rates

HN003NCT02775812	I	Adjuvant pembro, cisplatin and IMRT	high risk stage III-IV HSNCC	DLT

NCT02641093	II	Adjuvant pembro, cisplatin and IMRT	high risk stage III-IV HSNCC	Treatment related adverse events (TRAE)Disease free survival (DFS)


	Intervention	Control

All costs	USD	% total costs	USD	% total costs

Personnel	87 926	58.4	56 632	60.5

 CHWs (salaries and incentives)	10 332	6.9	3 982	4.3

 Field supervision and medical staff	28 193	18.7	17 194	18.4

 Management and technical staff	45 656	30.3	32 536	34.7

 Support staff (logistics, finance, administrative)	3 746	2.5	2 921	3.1

Programme costs	35 648	23.7	20 848	22.3

 Office and programme materials	1 756	1.2	1 324	1.4

 RUTF (supply)	17 795	11.8	5 648	6.0

 Training costs (trainer, location, supplies)	9 248	6.1	7 407	7.9

 Supervision and monitoring	6 849	4.6	6 469	6.9

Logistics	20 732	13.8	12 953	13.8

 Rent and utilities	8 927	5.9	2 767	3.0

 Transport (car rental, maintenance and fuel)	10 025	6.7	9 621	10.3

 RUTF transport and storage	1 780	1.2	565	0.6

Community contributions	6 218	4.1	3 208	3.4

 Costs to households	4 807	3.2	3 191	3.4

 Opportunity costs for community leaders	35	0.0	17	0.0

 Community-level rent	1 376	0.9	0	0.0

Total	150 523	100.0	93 641	100.0

Cost to government	11 881	7.9	5 341	5.7

Cost to partners	132 425	88.0	85 093	90.9

Cost to community	6 218	4.1	3 208	3.4


	Kegg pathway	Number of genes	Fold enrichment	p value*

UP	Steroid biosynthesis (cholesterol biosynthesis)	7	23.8	1.6E-07

Insulin signaling pathway	7	3.1	2.3E-02

Adipocytokine signaling pathway	5	5	1.6E-02

MAPK signaling pathway	9	2.5	2.4E-02

Glycolysis / Gluconeogenesis	4	4.5	5E-02

DOWN	Steroid biosynthesis (cholesterol biosynthesis)	4	27.8	3.3E-04

	Tight junction	6	5.3	4.6E-03


Details	HR-12 (current study)	93–11 [2]	IR-64 [3]	Kasalath [4]	Nipponbare [1]

Subspecies	indica	indica	indica	aus	japonica

Sequence depth	73x (Illumina) and 20x (PacBio)	4.2x (Sanger) and 36x (Illumina)	110x (Illumina)	6x (Roche 454) and 148X (Illumina)	6x (Sanger), 62x (Illumina) and 2.57x (Roche 454)

Sequencing technologies	Illumina and PacBio	Sanger and Illumina	Illumina	Illumina and Roche 454	Sanger, Illumina and Roche 454

Genome assembler(s)	MaSuRCA and PBJelly	RePS and SOAPDenovo	ALLPATHS-LG	Celera Assembler and String Graph Assembler	TIGR Assembler

Genome size (Mb)	389.77 (389.60)	374.55 (359.41)	345.9 (321.2)	401.14 (328.25)	374.47 (374.31)

No. of N's (Mb)	0.17	15.14	24.7	72.89	0.17

Total no. of contigs/scaffolds	59,692	50,231	26,160	51,550	NA

a. Anchored contigs/scaffolds	43,781	35,415	NA	36,932	NA

b. Unanchored contigs/scaffolds	15,911	14,816	NA	14,618	NA

N50 (Kb)	28.5	6.69	22.2	13.73	NA

No. of genes	56,284	40,464	37,758	53,662	55,986

CEG mapping (%)	94.35	95.97	94.35	95.97	95.97


Location	Posture	Interpretation

None	None	No heat imprint found in frame. Due to the lack of heat imprint in frame, neither location nor posture can be identified.

Bed	Sitting Laying	The individual is either sitting up in bed or laying in bed. The heat imprint is within bed boundaries.

Bedrail	Sitting Laying	The individual is either sitting on the bed with legs partly outside bed, laying in the bed on the bedrail, or sitting on the floor with parts of the upper body, e.g., arms, in the bed. The latter is interpreted as laying on the bedrail. Laying on bedrail is considered hazardous.

Floor	Standing Sitting Laying	The person is either standing on the floor, sitting on the floor, or laying on the floor


Groups	Day post-challenge

 	7	17	21	28

PCV2 in serum

Vaccinated group	3 of 5	3 of 5	2 of 5	0 of 5

Control group	5 of 5	5 of 5	5 of 5	5 of 5

Viral load in positive pigs

Vaccinated group	7.69 ± 0.11	7.67 ± 0.22	7.76 ± 0.26	0.00 ± 0.00

Control group	8.31 ± 0.40	8.41 ± 0.91	8.77 ± 0.55	7.72 ± 0.55


Manufacturer	Model	AEC System	Number of Times Tested

GE	Discovery 670a	AutomA 3D (AutomA & SmartmA)	2

GE	Discovery 670 Proa	1

GE	Discovery 690a	8

GE	Discovery 710a	1

GE	LightSpeed Ultra	5

GE	VCT	5

Philips	Gemini TFa	DoseRight 2.0	8

Siemens	Definition (Dual Source)		6 (12)

Siemens	Definition AS		8

Siemens	Definition AS+		3

Siemens	Definition AS+		1

Siemens	Definition Edge		1

Siemens	Emotion 16		2

Siemens	Sensation 16		7

Siemens	Sensation 16	CARE Dose 4D	5

Siemens	Sensation 64		6

Siemens	Sensation 64		7

Siemens	Sensation 64		6

Siemens	Sensation Openb		8

Siemens	Sensation Openb		6

Siemens	Sensation Openb		7

Siemens	Symbia Ta		2

Toshiba	Aquilion CXL	SURE Exposure 3D	4


Code	Communication items	Inpatient	Outpatient

 	 	Explaining	Breaking bad news	Discussing with a family	Explaining a diagnosis	Managing time	Managing a difficult consultation

1	Announcing the duration of the consultation	 	 	 	 	x

2	Establishing initial rapport	x	x	x	x	x	x

3	Setting the medical agenda	x	x	x	x	x	x

4	Introducing each other	 	 	x

5	Negotiating the agenda	 	 	x	x	x	x

6	Announcing	 	x

7	Exploring patient’s perspectives	x	x	x	x	x	x

8	Exploring patient’s understanding of what has happened	 	 	 	 	 	x

9	Summarizing the context	x	x	x	x	x	x

10	Informing	x	x	x	x	x	x

11	Clarifying roles, rules	 	 	x

12	Using clear language/no jargon	x	x	x	x	 	x

13	Chunking and checking (by open-ended questioning, reflecting, silence)	x	x	x	x	x	x

14	Empathy/legitimating	x	x	x	x	x	x

15	Making information circulate between participants	 	 	x

16	Being supportive	x	x	x	x	x	x

17	Summarizing	x	x	x	x	x	x

18	Planning the future	x	x	x	x	x	x

19	Remaining calm	 	 	x	 	 	x

20	Checking patient’s understanding at the end	x	x	x	x

21	Non verbal	x	x	x	x	x	x

22	Defining the limits	 	 	x	 	 	x

23	Negotiating a common solution with the patient	 	 	x	 	 	x

24	Maintaining the frame	 	 	 	 	x	x

25	Acknowledging the problem	 	 	 	 	 	x

26	Apologizing	 	 	 	 	 	x


Histopathology	Pediatrics	Adults	All patients

n (%)

Pineal region tumors	4 (10)	2 (5)	6 (14)

Colloid cyst	-	6 (14)	6 (14)

Pilocytic astrocytoma	3 (10)	2 (5)	5 (12)

Central neurocytoma	1 (2)	4 (10)	5 (12)

Glioblastoma	1 (2)	3 (7)	4 (10)

Atypical teratoid rhabdoid tumor	3 (7)	-	3 (7)

Ependymoma	-	2 (5)	2 (5)

Meningioma	-	2 (5)	2 (5)

Lymphoma	-	1 (2)	1 (2)

Choroid plexus papilloma	1 (2)	-	1 (2)

Anaplastic ependymoma	1 (2)	-	1 (2)

Anaplastic astrocytoma	1 (2)	-	1 (2)

Mature teratoma	1 (2)	-	1 (2)

Anaplastic oligodendroglioma	-	1 (2)	1 (2)

Craniopharyngioma	-	1 (2)	1 (2)

Glioneuronal tumor	1 (2)	-	1 (2)

Langerhans cell histiocytosis	1 (2)	-	1 (2)

Total	18	24	42


Visual area	Raw N PV	Corrected N PV	Raw N dual-labeled	Corrected N dual-labeled	% dually-labeled

V1	293	205	235	164	80

MT	293	205	218	153	75


	Total (£)

Trial Website:

Implementation of the consent process and the randomization and group assignment system	470

Implementation of the primary and secondary outcome questionnaires, including the code	1,410

Basic e-mail reminders system and follow-up questionnaires system	1,645

Control Website:

Implementation of the control site (estimated about 15-20 pages of information)	1,645

Intervention Website:

Implementation of the three modules, based on restructuring some old content and adding more new content provided by research team	5,875

SUB TOTAL:	11,045

Technical consultancy & project management	7,050

AGREED SPEND AT OUTSET:	18,095

VAT @ 17.5%	3,167

TOTAL	21,262


Parameter	HR point estimate	95% CI	p-value

Continuous variables

Age (years)*	1.05	0.81-1.37	0.722

Gleason score	0.82	0.71-0.96	0.012

PSA#	1.00	0.89-1.13	0.001

Linear interaction term with time°	1.03	1.01-1.06

ALP#	1.07	0.99-1.16	0.074

LDH#	1.22	1.02-1.46	0.027

Categorical variables

Staging at diagnosis

 M0	1

 M1	0.92	0.59-1.45	0.733

Metastatic sites

 Bone only	1

 Other	0.80	0.40-1.59	0.526


Statement	Online simulator superior	Equivalent	Atlas or lecture superior	Unsure

Learning tympanic membrane anatomy	45.5%	45.5%	0.0%	9.1%

Learning external auditory canal anatomy	63.6%	36.4%	0.0%	0.0%

Learning otoscopy technique	63.6%	27.3%	0.0%	9.1%

Availability of training technique	54.5%	9.1%	27.3%	9.1%


LncRNA name	Target	Cell type	Organism/system

FAL1	p21	Cancer cells	Human/in vitro

BANCR	p21	Colorectal cancer cells	Human/in vitro

LINCRNA-p21	p21	Mouse embryonic fibroblasts	Mouse/in vivo and in vitro

MALAT1	p53	Human osteosarcoma cells	Human/in vitro

7SL	p53	HeLa cells	Human/in vitro

VAD	INK4 locus/p16INK4a	hTERT-immortalized WI38 human fibroblasts	Human/in vitro

ANRIL	INK4 locus/p16INK4a	WI38 cell line	Human/in vitro

MIR31HG	INK4 locus/p16INK4a	Immortalized human diploid fibroblasts, TIG3-hTERT	Human/in vitro

UCA1	p16INK4a mRNA	Mouse primary cells	Mouse/in vitro

SAL-RNA	p53	WI38 cell line (old versus young)	Human/in vitro

SALNR	NF-90 localization	Human fibroblast cells	Human/in vitro

TERRA	Telomere length	Mammalian cells and medulloblastoma

ASNCMTRNA2	hsa-miR-4485	Human endothelial cells	Human/in vitro

HOTAIR	E3 ubiquitin ligase and PRC2	Ovarian cancer cells and HeLa cells	Human/in vitro

PANDA	PRC1 and PRC2 recruitment	Primary human diploid fibroblast strains, BJ (neonatal foreskin), and WI38 (fetal lung)	Human/in vitro


Characteristic

Age, years	69.6 ± 17.0a

Male sex, no. (%)	187 (61.9)

Smoking status

 Current smoker, no. (%)	73 (24.2)

 Pack-years for smokers	40.1 ± 24.2a

Antibiotic pretreatment (%)	61 (20.2)

Coexisting illnesses, no. (%)

 Coronary artery disease	97 (32.1)

 Hypertensive heart disease	78 (25.8)

 Congestive heart failure	16 (5.3)

 Peripheral vascular disease	20 (6.6)

 Cerebrovascular disease	16 (5.3)

 Renal dysfunction	81 (26.8)

 Liver disease	31 (10.3)

 Diabetes mellitus	61 (20.2)

 Chronic obstructive pulmonary disease	76 (25.2)

 Neoplastic disease	48 (15.9)

History, no. (%)

 Cough	270 (89.4)

 Sputum	221 (73.2)

 Dyspnea	229 (75.8)

Examination, no. (%)

 Rales	271 (89.7)

Laboratory findings

 CRP (mg/l), median (IQ range)	129.7 [65–211]

 Procalcitonin (μg/l), median (IQ range)	0.5 [0.2–2.2]

 Leukocyte count (× 109)	13.6 ± 6.7a

 proADM (pmol/l), median (IQ range)	1.1 [0.6–1.9]

Radiographic findings, no. (%)

 Pleural effusion	37 (12.3)

 Multilobar CAP	53 (17.5)

PSI points	99.4 ± 35.3a

PSI class, no. (%)

 I, II and III	120 (39.7)

 IV	130 (43)

 V	52 (17)


Gene Symbol	Gene Name	Entrez Gene ID	Fold difference DA/Cia5a	p-value*

 	Anti-inflammatory and regulators of immune responses

Scd1	stearoyl-Coenzyme A desaturase 1	246074	54.62	0.0001

Timp3	TIMP metallopeptidase inhibitor 3	25358	11.48	0.000000003

Adipoq	adiponectin, C1Q and collagen domain containing	246253	10.96	0.000003

Ptpn11	protein tyrosine phosphatase, non-receptor type 11	25622	4.18	0.00002

Cyp2j3	cytochrome P450, family 2, subfamily j, polypeptide 3	313375	3.38	0.002

Ptgis	prostaglandin I2 (prostacyclin) synthase	25527	2.63	0.0003

Cat	catalase	24248	1.91	0.002

Gss	glutathione synthetase	25458	1.56	0.001

Sod1	superoxide dismutase 1, soluble	24786	1.53	0.00002

 	Nuclear receptors and an interacting protein

Rxrg	retinoid X receptor gamma, Nr2b3	83574	5.39	0.0001

Pparg	peroxisome proliferator-activated receptor gamma, Nr1c3	25664	5.32	0.00005

Rev-erba	Nr1d1	252917	3.41	0.004

Arp1	Nr2f2	113984	2.45	0.0002

Nrip1	nuclear receptor interacting protein 1	304157	2.35	0.00004

Thrb	thyroid hormone receptor beta, Nr1a2	24831	2.07	0.002

Thra	thyroid hormone receptor alpha, Nr1a1	81812	1.97	0.001

Ncor1	nuclear receptor co-repressor 1	54299	1.89	0.003

Rora	RAR-related orphan receptor alpha, Nr1f1	300807	1.88	0.0001

Lxra	Liver X receptor alpha, Nr1h3	58852	1.52	0.0006


Variable	Frequency	Median (IQR) or percentage

Age in years	740	35 [27–42]

Age group

 ≥45 years	156	21.1

 <45 years	584	78.9

Sex

 Male	275	37.2

 Female	465	62.8

Marital status

 Married	278	37.6

 Divorced	160	21.6

 Widow	154	20.8

 Single	51	6.9

WHO stage

 3 & 4	261	35.3

 1 & 2	479	64.7

Baseline CD4 (cell/μl)	740	256 [132–469]

Baseline CD4 group

 ≤200 cell/μl	258	34.9

 >200 cell/μl	482	65.1

Hemoglobin (g/dL)	740	11.4 [9.7–13.1]

Normal HB	452	61.1

Anemia total	288	38.9

 Mild anemia	147	19.9

 Moderate anemia	88	11.9

 Severe anemia	53	7.2

OI on diagnosis

 Tuberculosis	197	26.6

 Others	543	73.4

Outcome on ART

 Median time (Mo)	740	27 [17–37]

 Dead	86	11.6

 Alive	654	88.4


Strain	AltDE	AltDE1

Total genes in the genome	4389	4748

Total core genes in the genome (%)a	3631 (83)	3631 (76)

Total flexible genes in the genome (%)a	758 (17)	1117 (24)

Comparison	Temperature (13-25°C)	Media (RM-MMG)	Media (MMG-STR)	Temperature (13-25°C)	Media (RM-MMG)	Media (MMG-STR)

Total genes differentially expressed (%)a	985 (22)	1037 (24)	1627 (37)	1026 (22)	1362 (29)	2771 (58)

Total core genes differentially expressed (%)b	763 (21)	809 (22)	1286 (35)	684 (19)	978 (27)	2143 (59)

Contribution of core genes to total genes differentially expressed	77%	78%	79%	67%	72%	77%

Total flexible genes differentially expressed (%)c	222 (29)	230 (30)	342 (45)	342 (30)	384 (34)	629 (56)

Contribution of flexible genes to total genes differentially expressed	23%	22%	21%	33%	28%	23%


Food (utensil)	Accuracy

Meat (fork and knife)	127%

Sides (fork)	82.6%

Soup (spoon)	60.2%

Pizza (hands)	87.3%

Soda (hands)	81.7%

Smoothie (straw)	57.7%

Total	81.2%


	Unst. est.	SE	St. est.	CR

Harsh discipline

 Physical discipline	1.37	0.30	.82	4.63***

 Emotional discipline	1.00	-	.70	-

Internalizing problems

 Harsh discipline	1.45	0.33	.50	4.35***

 Emotional symptoms (SDQ)	1.00	-	.62	-

 Peer problems (SDQ)	0.52	0.09	.45	5.64***

 Depressive symptoms (CDI)	1.91	0.32	.61	5.99***

Working memory

 Harsh discipline	−2.23	2.19	-.08	−1.02

 Block-Tapping test forward	1.00	-	.83	-

 Block-Tapping test backward	0.92	0.20	.71	4.59***

School performance

 Harsh discipline	−0.01	0.09	-.01	−0.12

 Working memory	0.01	0.03	.31	3.80***

 School grades English	1.22	0.11	.74	10.97***

 School grades Mathematics	1.14	0.11	.70	10.56***

 School grades Swahili	1.00	-	.61	-

 School grades Science	1.35	0.12	.83	11.51***


Factor	Chi-square	Significance

Female sex	255.97	p. < 0.01

Family history of osteoporosis	3.11	p. < 0.01

Previous fracture	1.51	p. < 0.01

Underweight	20.04	p. < 0.01

Steroids	7.21	p. < 0.05

Rheumatoid Arthritis	2.86	ns

Nephrolithiasis*	3.00	ns

Thyroid*	3.85	ns

Early menopause	47.36	p. < 0.01

Amenorrhea > 12 months	0.15	ns

Ovariectomy by age 50	44.61	p. < 0.01

Alcohol consumption	0.11	ns

Smoking habit	6.18	p. < 0.05

Exercise < 30 min/day	0.17	ns

Avoiding dairy products	10.50	p. < 0.01

Exposure to sunlight	8.85	p. < 0.05

Crohn disease*	0.74	ns

Celiac disease*	0.31	ns

Rectocolitis ulcerosa*	0.40	ns

Secondary osteoporosis*	15.20	p. < 0.01


	Telencephalon	Opctic tecta	Cerebellum	Medulla	Hypothalamus

Olfactory bulbs	1.06	1.02	1.23	1.15	1.04

Telencephalon		0.96	1.16	1.08	0.98

Optic tecta			1.21	1.13	1.03

Cerebellum				0.93	0.85

Medulla					0.91


Variable	Odds ratio	95% confidence interval

Sex

 Male	1.00	—

 Female	2.93	1.29–6.67

Posttest HIV counselling

 No	1.00	—

 Yes	2.96	1.22–7.19

Used contraception to prevent risk of transmission of HIV to partner

 No	1.00	—

 Yes	2.30	1.01–5.20

Used contraception due to partner's preference

 No	1.00	—

 Yes	2.76	1.08–7.06

Last CD4 cell count (per increase of 50 cells/mL)	0.73	0.62–0.87


	European Americans	African Americans	Mexican Americans

	With noise (%)	Denoised (%)	With noise (%)	Denoised (%)	With noise (%)	Denoised (%)

Europe	100	100	97	94	100	98

Africa	1	0	99	99	91	80

America	29	7	32	10	100	100

East Asia	1	0	20	4	76	27

Oceania	6	0	10	3	18	0

Central Asia	11	1	30	3	38	7


f	1/2	5/8	3/4	7/8	1

model A: simple	69	59	47	32	16

model B: treated class	62	53	42	31	19

model C: day care	80	73	62	43	20

model E: dual transmission	79	71	61	47	29


Amino acid	No. residues/100 residues

Arginine	7.12

Histidine	3.39

Isoleucine	3.76

Leucine	7.71

Lysine	9.18

Methionine	3.52

Phenylalanine	4.46

Threonine	4.67

Tryptophan	0.19

Valine	5.17

Indispensable AA (IAA)	49.16

Alanine	5.70

Aspartic acid	10.45

Cystine	1.05

Glutamic acid	15.72

Glycine	6.56

Proline	3.61

Serine	4.10

Tyrosine	3.65

Dispensable AA (DAA)	50.84


Anatomical region	BA	x	y	z	Z-value	Extent

R lingual/paraH gyrus	19/30	18	−51	−3	5.03	109

R lingual gyrus	19	18	−59	−5	3.54

L lingual/paraH gyrus	19/30	−16	−47	−3	4.91	227

		−8	−62	0	3.50

L post. cingulate gyrus	23/31	−12	−56	12	3.50

Lingual gyrus	19/18	4	−58	1	3.63	16

R posterior insula/TTG	41	38	−17	16	4.49	45

L superior temporal gyrus	22	−50	−24	16	4.07	38

L MidFG/frontal pole	10	−34	51	16	4.00	21

L mPFC/ACC	10	−8	43	14	3.97	17

L anterior cingulate cortex	32	−14	34	19	3.87	20

		−22	36	15	3.18

Anterior cingulate cortex	32/24	0	47	0	3.39	14

L inferior frontal gyrus	44/45	−34	11	16	3.85	16

mPFC/frontal pole	10	−4	65	12	3.85	11

R MidFG/frontal pole	10	40	47	12	3.63	15

L precuneus	7	−16	−76	42	4.42	78

L posterior cingulate	31	−12	−33	31	4.19	13

R precuneus	7	12	−72	40	3.76	44

		14	−62	42	3.60

		12	−68	48	3.35

Cuneus	17/31	0	−71	11	3.44	10

Precuneus/post. cingulate	31/23	−2	−63	25	3.37	41

	31/23	−2	−68	33	3.35

R IPL/angular g./TPJ	40/39	40	−62	38	3.71	25

		34	−68	42	3.33

L MTG/angular g./TPJ	39	−34	−65	29	3.71	22

L IPL/angular g./TPJ	40/39	−51	−60	40	3.65	17

R hippocampus/ParaH g.	30/19	24	−39	−6	3.65	26

L superior temporal gyrus	22/42	−61	−26	16	3.59	15


Dataset	Number of sequences

GATA1	14,351

SOX2	4526

OCT4	3761

STAT3	2546

KLF1	945


Variables	Group 1 ISH positiveN = 10	Group 2 ISH negative N = 15	P

Patient age at LT	49 ±11	52 ±11	.66

Female gender (patient)	40%	13%	.13

Caucasian (patient)	90%	87%	.69

Recipient body mass index	31 ±7	29 ±6	.51

MELD at LT	14 ±5	18 ±9	.42

Genotype 1 (unknown in 1 patient per group)	56%	86%	.11

Donor age	47 ±13	43 ±14	.82

Female gender (donor)	40%	53%	.51

Caucasian (Donor)	90%	67%	.34

Cold ischemia time, hours	7 ±2	7 ±2	.74

Warm ischemia time, minutes	39 ±9	34 ±10	.28

Tacrolimus as primary immune suppressant	100%	83%	.23

Steroid bolus treated ACR	30%	40%	.61

LT to ISH biopsy interval, months	23 ±10	24 ±12	.91


Pin	I/O Attached	Action	States

L0	Red LED	move

L1	Green LED	turn

L2	Orange LED		gripper is open

L4	Yellow LED	bottle is collected

L3	Switch A	touching

L5	Switch B	see drop

L6	Switch C	see bottle

L7	Switch D	over drop


Pathway	miRNAs	Genes

MAPK signaling pathway	10	95

PI3K-Akt signaling pathway	9	106

Endocytosis	10	72

TGF-β signaling pathway	6	35

Wnt signaling pathway	9	58

Ubiquitin mediated proteolysis	8	49

Regulation of actin cytoskeleton	8	74


Gene	GeneBank accession number	Specific primer sequences (5’ to 3’)	Product size (bp)

αA-crystallin (CRYAA)	U05569	F: CGGGACAAGTTCGTCATCTT	203

 	 	R: GCAGACAGGGAGCAAGAGAG

Heat-shock protein 70 (Hsp70)	NM05345	1F: AAGTACAAAGCGGAGGACG	249

 	 	1R: GATGGGGTTACACACCTGC

 	 	2F: TGCTGATCCAGGTGTACGAG	185

 	 	2R: CGTTGGTGATGGTGATCTTG

Heat-shock protein 90α (Hsp90α))	NM005348.3	F: ACCCAGACCCAAGACCAACCG	141

 	 	R: ATTTGAAATGAGCTCTCTCAG

Superoxide dismutase (SOD)	NM000454.4	F: AGGGCATCATCAATTTCGAGC	430

 	 	R: CAAGGGAATGTTTATTGGGCG

αB-crystallin (CRYAB)	NM001885.1	F: TCACCTAGCCACCATGGACATCGCCA	541

 	 	R: CAAAAGCTTATTACTATTTCTTGGGGG

Metallothionein 1M (MT)	NM176870.2	F: GCAAAGAGTGCAAATGCACCTC	125

 	 	R: TCAGGCACAGCAGCTGCACT

Interleukin-6 (IL-6)	NM000600.2	F: CTGGTCTTTTGGAGTTTGAGGTATACC	295

 	 	R: CCATGCTACATTTGCCGAAGA

Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)	BC014085	F: GAAGGTGAAGGTCGGAGT	225

 	 	R: GAAGATGGTGATGGGATTTC


Characteristic	Doctors	Nurses

Sex

Female	7	5

Male	8	0

Age (years)

Mean	37	45

Range	26–53	38–53

Years of practice in total

Mean	13	24

Range	1.75–29	16–33

Years of practice in nephrology

Mean	9	20

Range	0.3–26	15–26


	Pre-Delphi questionnaire	Round 1	Round 2	Round 3

Consumers	16	13	13	9

Carers	3	2	0	0

Professionals	26	21	17	16


	Compound	Content (mg/g)

Panax ginseng	Rb1	2.24

Re	1.13

Rg1	1.47

Salvia miltiorrhiza	Salvianolia acid B	28.2

Tanshinone IIA	0.6


Parameter	Total (N = 193)

Reason for last admission

 Palliative procedure or surgery	28 (14.5)

 Gastrointestinal symptoms	52 (26.9)

 Cardiovascular or pulmonary symptoms	39 (20.2)

 Infectious state	31 (16.2)

 Uncontrolled pain	11 (5.7)

 Hematologic instability	12 (6.2)

 Neurologic symptom	7 (3.6)

 Others	13 (6.7)

ICU admission in the last month	23 (11.9)

Imaging examination conducted in the last month

 No examination	56 (29.0)

 Examination	137 (71.0)

CT	101 (73.7)

MRI	8 (5.8)

PET-CT	1 (0.7)

Combined imaging (>2)	27 (19.7)

Type of treatment administered during the last 6 mo

 Chemotherapy alone	155 (80.3)

 Chemotherapy with radiation	26 (13.5)

 Chemotherapy with surgery	12 (6.2)

Gastrointestinal surgery	9

Pelvic exenteration	2

Neuro-surgery	1

Type of chemotherapy-agent administered during the last 6 mo

 IV only	177 (91.7)

 IV with PO	16 (8.3)


Element	Measurement

Ulna (NMMNH P-19460), length of semilunar notch	24.5*

Ulna (NMMNH P-19460), depth of semilunar notch	6.2*

Ulna (NMMNH P-19460), maximum mediolateral breadth	21.5

Radius (NMMNH P-19460), length	93.0

Radius (NMMNH P-19460), anteroposterior midshaft diameter	11.0

Radius (NMMNH P-19460), midshaft mediolateral diameter	11.5

Metacarpal II (NMMNH P-19460), length	25.0

Metacarpal II (NMMNH P-19460), proximal breadth	9.8

Metacarpal II (NMMNH P-19460), midshaft mediolateral diameter	8.7

Metacarpal II (NMMNH P-19460), distal breadth	12.4

Metacarpal III (NMMNH P-19640), length	29.3

Metacarpal III (NMMNH P-19640), proximal breadth	13.9

Metacarpal III (NMMNH P-19640), midshaft mediolateral diameter	9.8

Metacarpal III (NMMNH P-19640), distal breadth	13.5

Metacarpal IV (NMMNH P-19640), length	23.9

Metacarpal IV (NMMNH P-19640), proximal breadth	10.9

Metacarpal IV (NMMNH P-19640), midshaft mediolateral diameter	6.8

Metacarpal IV (NMMNH P-19640), distal breadth	9.9

Ungual (NMMNH P-19640), proximal breadth of most complete	8.6


First author	Year	Skin condition

Praveenkumar et al. [29]	2016	Psoriasis

Kokpol et al. [30]	2014	Psoriasis

Henseler et al. [31]	1995	Psoriasis

Owczarczyk-Saczonek et al. [34]	2015	Psoriasis

Gisondi et al. [26]	2007	Psoriasis

Nagpal et al. [51]	2016	Acne

Del Prete et al. [52]	2012	Acne

Akin Belli et al. [54]	2016	Rosacea

Shlyankevich et al. [56]	2014	Hidradenitis suppurativa

Banger et al. [61]	2015	Androgenic alopecia

El Sayed et al. [62]	2016	Androgenic alopecia

Saleh et al. [66]	2014	Lichen planus

Arias-Santiago et al. [65]	2011	Lichen planus

Lee et al. [68]	2017	Atopic dermatitis

Ambiel et al. [71]	2014	Pemphigus

Saylam Kurtipek et al. [83]	2015	Holoderma

Wali et al. [84]	2016	Striae

Chen et al. [85]	2016	Acanthosis nigricans

Puttegowda et al. [75]	2015	Tendon xanthomas

Nagase et al. [76]	2013	Skin aging

Penington et al. [86]	2007	Wound healing


MIGS ID	Property	Term	Evidence codea

		Domain Bacteria	TAS [13]

		Phylum Bacteroidetes	TAS [14,15]

		Class Bacteroidia	TAS [14,16]

	Current classification	Order Bacteroidales	TAS [14,17]

		Family Rikenellaceae	TAS [14,18]

		Genus Alistipes	TAS [5,19]

		Species Alistipes timonensis	IDA

		Type strain JC136T	IDA

	Gram stain	Negative	IDA

	Cell shape	Bacilli	IDA

	Motility	Nonmotile	IDA

	Sporulation	Nonsporulating	IDA

	Temperature range	Mesophile	IDA

	Optimum temperature	37°C	IDA

MIGS-6.3	Salinity	Growth in BHI medium + 1% NaCl	IDA

MIGS-22	Oxygen requirement	Anaerobic	IDA

	Carbon source	Unknown	NAS

	Energy source	Unknown	NAS

MIGS-6	Habitat	Human gut	IDA

MIGS-15	Biotic relationship	Free living	IDA

MIGS-14	PathogenicityBiosafety levelIsolation	Unknown2Human feces	NAS

MIGS-4	Geographic location	Senegal	IDA

MIGS-5	Sample collection time	September 2010	IDA

MIGS-4.1	Latitude	13.7167	IDA

MIGS-4.1	Longitude	16.4167	IDA

MIGS-4.3	Depth	Surface	IDA

MIGS-4.4	Altitude	51 m above sea level	IDA


 	Correct reactions	Correct

 	(ignoring enzyme)	(including enzyme)

Pantothenate and coenzyme A biosynthesis pathway

Recall(P) (%)	78 (7/9)	56 (5/9)

Precision (%)	59 (24/41)	41 (17/41)

Tetrahydrofolate biosynthesis pathway

Recall(P) (%)	90 (9/10)	70 (7/10)

Precision (%)	60 (39/65)	38 (25/65)

Aerobic fatty acid β-oxidation I pathway

Recall(P) (%)	29 (2/7)	29 (2/7)

Precision (%)	30 (11/37)	14 (5/37)


Folates	Methionine cycle	Transsulfuration	Other

THF = 4.61	Met = 49.2	Cysta = 36.9	Ser = 563

510CH = 0.28	SAM = 81.1	Cys = 195	Gly = 924

510CH2 = 0.51	SAH = 19.1	GluCys = 9.8	Sarc = 9.16

10fTHF = 3.41	Hcy = 1.12	GSH = 6591	DMG = 0.71

5mTHF = 4.50		GSSG = 61.3	Aicart = 0.94

DHF = 0.039		Glut = 3219	HCOOH = 13.1


Experimental phase	Correlation	Brain regions	x	y	z	Cluster size	t value	p value FWE

Fear conditioning	Positive	Posterior cingulate cortex	12	−34	46	70	3.10	0.033

Posterior insular cortex	44	−38	24	116	3.22	0.034

Amygdala	16	2	12	140	3.32	0.037

Hypothalamus	−12	0	−8	33	2.71	0.039

Anterior insular cortex	36	28	6	138	3.09	0.051

Negative	Orbitofrontal cortex	−16	34	−24	21	3.21	0.038

Subgenual anterior cingulate cortex	−6	18	−18	48	3.00	0.039

Shock delivery (unconditioned responses)	Positive	Hypothalamus	8	4	−32	357	4.11	0.015

Middle insular cortex	−40	2	8	311	3.53	0.040

Negative	Orbitofrontal cortex	−14	34	−18	44	3.40	0.011

Late extinction learning	Positive	Subgenual anterior cingulate cortex	−14	26	−14	30	2.88	0.028

Negative	Middle insular cortex	−36	4	16	62	3.27	0.024

Early extinction recall	Positive	Parahippocampus	−30	2	−20	183	5.35	0.001

Subgenual anterior cingulate cortex	10	12	−18	64	4.39	0.002

Anterior insular cortex	32	18	12	82	4.35	0.003

Anterior insular cortex	−62	10	0	1595	5.34	0.005

Dorsal anterior cingulate cortex	10	24	40	91	4.13	0.005

Ventromedial prefrontal cortex	−14	40	−26	572	4.37	0.014

Middle cingulate cortex	−4	0	36	76	3.33	0.024

Orbitofrontal cortex	−16	52	−18	572	3.94	0.034


Reference	Measurement of PAH-RPF/true RPF (n/n)	PAH-RPF (ml/min)	True RPF (ml/min)

[17]	6 (0)	-	690

[18]	40 (11)	475	1116

[19]	22 (6)	474	1238


	accepted marine species in WORMS	18S V9 OTUs in planktona

Acanthocephala	468	0

Annelida	12 862	404 (48)

Arthropoda	57 871	9497 (205)

Brachiopoda	396	8 (4)

Bryozoa	6167	15 (5)

Cephalorhyncha	238	13

Chaetognatha	131	531 (7)

Chordata	22 248	6972 (32)

Cnidaria	11 407	842 (82)

Ctenophora	192	33 (9)

Cycliophora	2	0

Dicyemida	122	1

Echinodermata	7252	74 (19)

Entoprocta	180	12

Gastrotricha	497	2

Gnathostomulida	98	0

Hemichordata	130	12 (3)

Mollusca	45 219	560 (89)

Nematoda	7152	30 (6)

Nemertea	1359	81 (4)

Orthonectida	25	0

Phoronida	19	0

Placozoa	1	0

Platyhelminthes	12 230	148 (12)

Porifera	8476	25 (4)

Rotifera	187	7 (2)

Sipuncula	147	0

Tardigrada	193	2

Xenacoelomorpha	433	0

unassigned metazoan	n.a.	402

total	195 702	19 671 (531)


Level of lesion	Number of patients	Percentage

Thoracic	3	3.49

Thoracolumbar	6	6.98

Lumbar	23	26.74

Lumbosacral	18	20.93

Sacral	16	18.60

Sacrococcygeal	1	1.16

Not available	19	22.09

Total	86	100


	β	t	p

Maternal age (per year)	−0.008	−0.45	0.65

Maternal weight (per kg)	0.211	11.77	<0.001

Frozen thawed embryo (versus fresh embryo)	0.079	4.25	<0.001

ICSI (versus IVF)	0.009	0.48	0.63

SAGE (versus Vitrolife)	−0.004	−0.24	0.81

Gestational age	0.490	27.38	<0.001

Gender (male versus female)	0.110	6.33	<0.001


	Secretory uric acid transporter

Compound	OAT1	ABCG2

Lesinurad	3.90 ± 0.94	>100


Pathway	Description

G protein-coupled receptor (GPCR) signaling	There are more than 800 GPR genes in the genome. These receptors activate adenyl cyclase to produce cAMP from ATP, or in the phosphatidylinositol pathway to produce a cell response, depending on the context. Sixteen of these receptors were deregulated in our tumor series (available upon request).

EGFR signaling	This receptor was markedly downregulated. In addition, SOS1 (present in cytosol) was upregulated in this pathway.

ErbB2 signaling	The ligand NRG1 and its receptors ErbB2 and ErbB3 were upregulated. The ErbB2 interacting protein (ERBB2IP) was also upregulated. However, the ErbB4 signaling pathway was not deregulated.

Integrin cell surface interactions	Integrin αIIb β3 signaling presented four upregulated elements. The amyloid β (A4) precursor protein-binding family B member 1-interacting protein (APBB1IP) and downstream effector Talin-1 (TLN1) were upregulated. This upregulation provoked the activation of integrin αIIb β3 and the subsequent activation of tyrosine-protein kinase SYK (SYK), which was also upregulated, by Src.


Characteristic	Case (n = 82)

Age in years

> 45	21

≤ 45	61

Sex

 Male	33

 Female	49

Tumour size, cm	5.94 ± 2.65

Location

 Left	31

 Right	51

Symptoms

 Asymptomatic	48

 Symptomatic	34

Fuhrman grade

 1 to 2	32

 3 to 4	50

TNM stage

 I to II	49

 III to IV	33

pT status

 T1 to T2	64

 T3 to T4	18

pN status

 N0	59

 N1	23

pM status

 M0	78

 M1	4

Surgical treatment

 Radical	55

 Partial	27

Tumour thrombus

 Negative	72

 Positive	10


Annual Report Year	Case Number	Clinical Summary

Patients Treated with FabAV

2001	55	A 17-year-old girl presented after apparent intravascular envenomation by an unknown snake with features of anaphylaxis to venom. Within minutes, she was hypotensive, profoundly hypoxic, developed pulmonary edema, and had a seizure. Treatment included intubation with ventilator support, dopamine, and FabAV (dose not reported). She never developed local tissue effects or coagulopathy. Despite maximal therapy, she died five days after envenomation.

2002	69	A 43-year-old man presented with severe hypotension after a rattlesnake bite. He remained hypotensive despite fluids, dopamine, epinephrine, diphenhydramine, steroids, and 26 vials of whole-IgG antivenom. Disseminated intravascular coagulopathy developed. He then received six vials of FabAV, after which his blood pressure improved such that vasopressors were discontinued. He developed epistaxis and oral mucosal bleeding that was treated with 7 additional vials of whole-IgG antivenom and transfusions of platelets, fresh frozen plasma, and cryoprecipitate (response not reported). He developed renal failure, and ultimately died of multi-system organ failure.

2003	424	A 33-year-old man received FabAV for an apparently uncomplicated rattlesnake envenomation. He was discharged from the hospital 24 hours later with only minimal symptoms, and was given a prescription for oxycodone with acetaminophen. He died of an apparent overdose of oxycodone that night.

2004	52	A 52-year-old man presented with a forearm compartment syndrome due to a copperhead snakebite. He received FabAV and underwent a dermotomy of his finger and a fasciotomy of his arm. Subsequently, he developed severe alcohol withdrawal, which was treated with diazepam, haloperidol, and fentanyl, which led to respiratory arrest, aspiration, and acute respiratory distress syndrome. Medical care was withdrawn, and the patient died.

2004	53	A 55-year-old man presented with severe hypotension and coma from apparent intravascular envenomation from a rattlesnake. FabAV therapy and aggressive resuscitation were not initiated for several hours. The patient developed renal failure, disseminated intravascular coagulopathy, and circulatory collapse, and died seven hours after envenomation.

Patients Treated with Unspecified Antivenom

2001	56	A 30-year-old man presented comatose after rattlesnake envenomation. On presentation, he was found to have coagulopathy, thrombocytopenia, and a subarachnoid hemorrhage. He received "10 to 20 vials" of unspecified antivenom, but died after withdrawal of life support.

2005	57	A 32-year-old man presented to the emergency department in respiratory arrest due to anaphylaxis from a rattlesnake bite. He received unspecified antivenom, and subsequently died of anoxic encephalopathy.


	N	Drug	Duration	Subcutaneous adipose tissue	Visceral adipose tissue	Body mass index (kg/m2)	Reference

No change in SAT	30	Rosi versus placebo	24 weeks	MRI: NS	MRI: NS	NS	Sutinen et al. [55]

	108	Rosi versus placebo	48 weeks	DEXA limb fat: NS CT thigh: NS CT s.c. abdomen: NS	CT: NS	NS	Carr et al. [56]

	14	Pio versus feno versus pio + feno versus placebo	12 months	DEXA upper limb fat: NS DEXA lower limb fat: NS CT s.c. abdomen: NS	CT: NS	NS	Gavrila et al. [65]

	96	Rosi versus placebo	24 weeks	DEXA limb fat: NSDEXA arm fat: NS DEXA leg fat: NS	ND	NS	Cavalcanti et al. [62]

Increase in SAT	28	Rosi versusplacebo	3 months	CT thigh (cm2): rosi: + 2.3 versus pla −0.9, Δ rosi versus pla, P = .002CT s.c. abdomen: NS DEXA leg: NS (rosi +50 g versus pla −80 g,Δ rosi versus pla P = .08)	CT: NS	NS	Hadigan et al. [57]

	105	Rosi versus metformin versus rosi + met versus placebo	16 weeks	DEXA leg fat (%): rosi: +4.8,*NS; met: −3.6,*NS; rosi + met: −0.5,*NS; pla: −8.3%,*NS Δ rosi vs pla P = .03, other groups versus pla, NSDEXA arm fat: NS DEXA limb fat: NS CT s.c. abdomen: NS	CT (%): rosi: 0.0,*NS; met: −0.6,*NS; rosi + met:−7.9,*NS; pla: −7.2,*NS Δ rosi versus pla, P = .08, other groups versus pla, NS	Body mass index ND, body weight (kg): rosi: 0.0,*NS; met: −2.0,*P < .001; rosi + met: −1.5,*P < .01; pla:−0.05,*NS Δ met versuspla, P = .03; Δ met + rosi versuspla, P = .06	Mulligan et al. [60]

	130	Pio versus placebo	48 weeks	DEXA limb fat (g): pio: +380 g; pla: +50 gΔ pio versus pla P = .051 CT s.c. abdomen: NS	CT: NS	Pio: +0.9; pla: +0.3Δ pio versus pla P = .07	Slama et al. [66]

	39	Rosi versus metformin	26 weeks	CT s.c. abdomen (cm2) rosi: +16,*P < .05; met: −11,*P < .05 Δ rosi versus met 27cm2 (95% CI, 7 to 46)	CT (cm2)rosi: −1,*NS; met: −25,*P < .05 Δ rosi versus met 24 cm2 (95% CI, 6 to 51)	Rosi: +0.4,*P < .05; met: −0.4,*P < .05 Δ rosi versusmet 0.7 (95% CI, 0.5 to 1.6)	van Wijk et al. [58]


	Group A (non-GBA)	Group B (GBA)	P value

Neck lymphadenopathy	26/60 (43%)	7/14 (50%)	NS

Fissured lips	53/60 (88%)	12/14 (86%)	NS

Strawberry tongue	47/61 (77%)	11/14 (79%)	NS

Conjunctivitis	55/60 (92%)	12/14 (86%)	NS

Skin rash	51/58 (88%)	15/15 (100%)	NS

BCG erythema change	25/58 (43%)	6/13 (46%)	NS

Induration of extremities	39/56 (70%)	3/12 (25%)	NS


Stimulus 1	Stimulus 2	95% CI Lower bound	Difference of Means (1–2)	95% CI Upper bound	P

TOTALLY ENGAGED (N = 27)

Audio only	Multimodal	–39.72	–28.33	–16.95	<0.001

Music: FAV	Audio only	27.69	39.07	50.46	<0.001

Music: FAV	Multimodal	–0.64	10.74	22.12	0.0682

FRUSTRATED (N = 27)

Audio only	Multimodal	–3.81	6.19	16.18	0.3023

Music: FAV	Audio only	–27.47	–17.48	–7.49	<0.001

Music: FAV	Multimodal	–21.29	–11.30	–1.31	0.0232


Activities Related to HAI Prevention	Professional Groups	N	Average Values in Groups	Median	Standard Deviation	95% CI

Hand-hygiene	Medical student	28	5.6	6.0	2.71	4.649, 6.494

Medical intern	18	6.2	7.0	2.71	4.873, 7.571

Physician	54	6.0	7.0	2.78	5.241, 6.759

Use of disposable gloves	Medical student	28	6.6	7.0	1.52	6.016, 7.198

Medical intern	18	5.0	5.5	2.57	3.724, 6.276

Physician	54	4.9	5.0	2.41	4.229, 5.548

Adherence to aseptic technique	Medical student	28	5.2	5.0	1.97	4.451, 5.978

Medical intern	18	5.5	6.0	2.50	4.255, 6.745

Physician	54	5.3	6.0	2.63	4.616, 6.051


Identified Motif Sequence	# Seqs withMotif	Motif E-Value	TRANS FAC Hit ID	TRANS AC Binding Site Sequence	TRANS FAC annotation

CATCCAACGGC	29	1.2E-1	M00227	TCCAACGGC	Myb

CCCGCCACGCGCCAC	48	5.1E-26	M00187	GCCACG<underline>T</underline>GCC	Helix Loop Helix

TGGCGGGA	50	5.8E-13	M00024	TGGCG<underline>C</underline>GA	Elongation Factor 2

CCAAACCC	50	2.7E-5	No Hit

CCACCACCACC	48	3.8E-16	No Hit

ACACAACACAC	45	2.2E-10	No Hit

AAAATAAAAATAAAA	9	2.27E-7	No Hit

AATAAAAAAATAAAA	8	1.51E-7	No Hit

AGCTAGCTAGC	6	1.47E-7	No Hit

AGCGAGCGAGC	4	6.23E-8	No Hit

AGCAAGCTAGC	3	2.47E-7	No Hit


	Number	Percentage (%)

1 year follow up	66	81.5

Lost to follow up	5	6

Deceased at 1 year	10	12.3

Referral done to specialized cardiology center	37	45.6

Underwent Exercise ECG	22	27

Underwent Coronary angiogram	10	12.3

Underwent Revascularization	7	7.3

Re-admitted with Coronary events	6	7.4


Modification	Hypotheses tested

Ranking task	Introducing the ranking task prior to the cTTO valuation will reduce the inconsistencies and improves the overall data quality (i.e. more WTD responses).

BTD/WTD split	Separating the BTD and WTD cTTO tasks will reduce the inconsistencies of the valuations and improve the overall data quality (i.e. more WTD responses, higher values for mild heath state and fewer spikes).

Feedback module	Presenting respondents with the rank ordering implied by their cTTO valuations will reduce the inconsistencies as they will identify and flag problematic valuations for removal from the data.


Viroid small RNAs (vd-sRNAs)	Reference

vd-sRNAs of peach latent mosaic viroid were used to study the viroid evolution and pathogenesis	Di Serio et al., 2009; Navarro et al., 2012a

Gaining further insights into the genesis and role of vd-RNAs of hop stunt viroid and grapevine yellow speckle viroid 1 in plant–viroid interaction	Navarro et al., 2009

vd-sRNAs from PSTVd-infected wild-type and RDR6i Nicotiana benthamiana plants accumulate to levels paralleling their genomic RNA, display similar patterns with prevailing 22- or 21-nt plus-strand species, and adopt strand-specific hot spot profiles	Di Serio et al., 2010

The pathway involved in the biogenesis of vd-sRNAs of hop stunt viroid was studied and revealed	Martinez et al., 2010

Characterization of vd-sRNA of hop stunt viroid, grapevine yellow speckle 1 and grapevine yellow speckle 2 viroids in grapevine	Alabi et al., 2012

vd-sRNAs of peach latent mosaic viroid (PLMVd) were characterized. Similarly to host microRNAs (miRNAs), two PLMVd vd-sRNA derived from the pathogenic determinant of an extreme albinism direct cleavage of a specific host mRNA, strongly suggesting their involvement in symptom expression	Navarro et al., 2012a

Based on the observation that viroid-infected plants generate vd-sRNAs 21–24 nt, an approach was developed to utilize several bioinformatic tools for identifying novel and known viroids and viroid-like circular RNAs in sRNA libraries	Wu et al. (2012)

vd-sRNAs derived from potato spindle tuber viroid variants inducing different symptoms, may aim at multiple and different host mRNA targets	Wang et al., 2011; Piernikarczyk et al., 2013

Computational algorithms as bioinformatic tools were utilized to identify circular RNAs of viroid or satellite sRNAs	Zhang et al., 2014

Extending the host range of apple dimple fruit viroid to fig	Chiumenti et al., 2014

Inoculation with a single variant of peach latent mosaic viroid generates a highly heterogeneous progeny within a single infected peach seedling. The most distant variants displayed a 17% variation level when compared to the parent sequence	Glouzon et al., 2014

vd-sRNAs of potato spindle tuber viroid (PSTVd) and effects of artificial miRNA derived from PSTVd-mild or -severe infected plants were analyzed. Differences in the distribution of vdsRNAs hot spots were observed. Data suggest involvement of vd-sRNAs in symptom expression	Adkar-Purushothama et al., 2015; Avina-Padilla et al., 2015

Extending the host range of hop stunt viroid to chickpea	Pirovano et al., 2015


Parameter	Value

	n = 4068

Age (n,%)

 18-34	20	0.5

 35-44	108	2.7

 45-54	513	12.6

 55-64	1,481	36.4

 > = 65	1,946	47.8

Geographic region (n,%)

 Northeast	538	13.2

 Northcentral	1,249	30.7

 South	2,071	50.9

 West	208	5.1

Payer type (n,%)

 HMO	81	2.0

 Indemnity	1,814	44.6

 PPO	1,210	29.7

 POS	941	23.1

 Other	21	0.5

Comorbidities (n,%)

 Cerebrovascular Disease	426	10.5

 Coronay heart disease	910	22.4

 Heart failure	66	1.6

 Peripheral arterial disease	165	4.1

 Diabetes	808	19.9

 Kidney Disease	60	1.5

 Liver Disease	272	6.7

 Respiratory Disease	2,384	58.6

Health care expenditures prior to index date (mean, SD)

 -365 days	28,562	31,136


Gene	Number of exons	Number of mutations worldwide**	Number of homopolymer repeats* in CDS	Function in hearing process

GJB2	2	> 220	0	ion homeostasis

SLC26A4	21	43	7	ion homeostasis

MYO15A	66	28	8	hair bundle, motor protein

OTOF	48	26	4	exocytose at auditory ribbon synapse

CDH23	69	21	4	hair bundle, adhesion protein

TMC1	24	20	4	unknown function

TMPRSS3	13	16	3	unknown function

TECTA	23	10	2	extracellular matrix protein

TRIOBP	24	9	7	hair bundle, cytoskeletal formation

TMIE	4	8	0	unknown function

PJVK	7	7	3	signaling of hair cells and neurons

ESPN	13	6	1	hair bundle, cytoskeletal formation

PCDH15	33	5	8	hair bundle, adhesion protein

ESRRB	12	5	1	transcription factor

MYO7A	49	5	5	hair bundle, motor proteins


Parameter	Temperature (K)

293 	303 	313

−ΔG° (kJ mol−1)	6.543	6.063	5.687

−ΔH° (kJ mol−1)	16.869

−ΔS° (kJ mol−1 K−1)	0.0353

Ea (kJ mol−1)	3.309


Participant code	Sex	Age (yrs)	BMI (kg/m2)	Injury level and AIS score	Years since SCI	Medications	Treatment

1	M	46	32.9	C5A	23.3	Baclofen, Temazepam	CPAP

2	M	68	27.7	C4A	23.9	Baclofen 	CPAP

3	F	28	20.3	C5A	4.10	Baclofen, Diazepam	—

4	M	42	20.8	C6A	17.10	Baclofen, Diazepam	Oral Splint

5	M	26	18.5	C6A	10.10	Baclofen 	—

Positive control

1	M	43	24.8	—	—	—	—

2	F	31	20.7	—	—	—	—


 	 	Women	Men

 	 	N = 214	N = 154

 	 	OR	p	OR	p

Surgical specialties	Combining work with family	0.4 (0.3–0.6)	.000	0.4 (0.3–0.7)	.000

 	Good salarya	1.9 (1.2–3.0)	.004	0.8 (0.5–1.3)	NS

 	In line with technical skills	1.4 (1.0–1.9)	.034	1.9 (1.2–3.0)	.011

 	Lots of direct patient contact	0.9 (0.6–1.3)	NS	0.6 (0.4–0.9)	.018

Non-surgical specialties	Research opportunities	1.4 (1.0–1.9)	.023	1.9 (1.3–2.9)	.001

 	Good salary	0.4 (0.2–0.6)	.000	0.8 (0.5–1.3)	NS

 	Interesting content	2.4 (1.0–5.5)	.048	1.7 (0.8–3.9)	NS

Family medicine	Lots of direct patient contact	3.7 (1.8–7.9)	.001	2.9 (1.4–6.0)	.005

 	Career prospectsa	0.4 (0.2–0.7)	.002	0.8 (0.4–1.5)	NS

 	Combining work with family	2.3 (1.3–4.2)	.004	1.6 (0.9 –2.9)	NS

 	Good salary	1.9 (1.1–3.3)	.018	1.7 (0.9–3.2)	NS

 	Interesting content	0.4 (0.2–0.9)	.024	0.8 (0.4–1.9)	NS

 	In line with technical skills	0.6 (0.4–1.0)	.045	0.7 (0.5–1.2)	NS

 	Research opportunities	0.8 (0.6–1.3)	NS	0.6 (0.4–1.0)	.031

Uncertain	Combining work with family	2.1 (1.5–3.1)	.000	1.8 (1.2–2.7)	.005

 	Lots of direct patient contact	0.6 (0.4–0.8)	.003	1.0 (0.7–1.5)	NS


Authors	Intervention	Patient Population	Design	No. of Patients	Outcome

Pizzocarro et al15	IFN-α2b v placebo	Robson stages II and III (T3aN0M0 and T3bN0M0 or T2/3N1-3M0)	Multicenter, randomized, controlled trial	247	5-year OS: 0.665 (control) v 0.660 (treatment) (HR 1.040; 95% CI, 0.671 - 1.613, P = 0.861)

5-year DFS: 0.671 (control) v 0.567 (treatment) (HR 1.412; 95% CI, 0.927–2.149, P = .107)

Messing et al16	IFN-α-NL v observation	pT3–4a and/or node-positive)	Multicenter, randomized, controlled trial	283	At 10.4 years median follow-up:

Median survival: 7.4 years (control) v 5.1 years (treatment) (P = .09).

DFS: 3.0 years (control) v 2.2years (treatment) (P = .33)

Clark et al17	IL-2 v observation	T3b-4 or N1–3 (LA) or M1	Multicenter, randomized, controlled trial	69 total; 44 LA, 25 M1 disease	2-year DFS: 48% (control in LA patients) v 53% (treatment in LA patients) (P = 0.73)

2-year OS: 77% (control in LA patients) v 86% (treatment in LA patients) (P = .38)

Passalacqua et al18	IL-2 and IFN-α v observation	pT1, T2, T3 a-b-c; pN0-pN3, M0	Multicenter, randomized, controlled trial	310	5-year DFS: 0.73 (control) v 0.73 (treatment)

10-year DFS: 0.60 (control) v 0.73 (treatment) (HR 0.84; 95% CI, 0.54–1.33, P = 0.47)

Atzpodien et al19	IL-2 and IFN-α2a and intravenous 5 v fluorouracil	pT3b/c pN0 or pT4pN0), pN, complete resection of tumor relapse or solitary metastasis (R0)	Multicenter, randomized, controlled trial	203	At median follow-up of 4.3 years:

2-year OS: 91% (control) v 81% (treatment)

5-year OS: 76% (control) v 58% (treatment)

8-year OS: 66% (control) v 58% (treatment) (P = 0.0278)

2-year DFS: 62% (control) v 54% (treatment)

5-year DFS: 49% (control) v 42% (treatment)

8-year DFS: 49% (control) v 39% (treatment) (P = 0.2398)

Aitchison et al22	IL-2 and IFN-α2a and intravenous 5-fluorouracil	T3b-c,T4 or any pT and pN 1 or pN 2 or positive microscopic margins or microscopic vascular invasion	Multicenter, randomized, controlled trial	309	3-year DFS: 50% (control) v 60% (treatment) (HR 0.87; 95% CI, 0.63-1.20)

5 year OS: 60% (control) v 68% (treatment) (HR 0.91; 95% CI, 0.60–1.38)

Galligioni et al24	Autologous irradiated tumor cells & BCG v observation	Stages I, II, and III	Prospective, randomized, controlled trial	120	At 61 months median follow-up:

5-year OS: 78% (control) v 69% (treatment)

5-year DFS: 72% (control) v 63% (treatment)

Adler et al25	Autologous irradiated tumor cells & BCG & hormone v hormone	All stages	Prospective, randomized, controlled trial	43	Trend for prolongation of DFS for stage I, II, and III

(P<.1)

Wood et al26	Autologous, tumor-derived heat-shock protein (glycoprotein 96)–peptide complex (HSPPC-96; vitespen) v observation	cT1b–T4 N0 M0, or cT any N1-2 M0	Multicenter, randomized, controlled trial	819	At 1.9 years median follow-up:

Recurrence: 39.8% (control) v 37.7% (treatment) (HR 0·923; 95% CI, 0·729–1·169, P = .506)

OS not mature

Jocham et al27	Autologous renal tumor cells (Reniale)	pT2–3b pN0–3 M0	Multicenter, randomized, controlled trial	558	At 5-year follow-up:

DFS: 67.8% (control) v77.4% (treatment) (P = .0204) At 70-month follow-up:

DFS: 59.3% (control) v 72% (treatment)

HR for tumor progression: 1.58 (95% CI 1.05–2.37) and 1.59 (1.07–2.36) (P = .0204)


Primary	Definition

Tumor (T)

Tx	Primary tumor cannot be assessed

T0	No evidence of primary tumor

Tis	Carcinoma in situ

T1	Tumor 2 cm or less in greatest dimension and no medullary bone invasion

T2	Tumor more than 2 cm but not more than 4 cm in greatest dimension and no bone invasion or tumor 2 cm or less in greatest dimension with medullary bone invasion

T3	Tumor more than 4 cm in greatest dimension and no medullary bone invasion or tumor more than 2 cm but not more than 4 cm with medullary bone invasion

T4a	Tumor more than 4 cm in greatest dimension with medullary bone invasion or tumor invades into mandibular canal, deep/extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), maxillary sinus, or skin of face

T4b	Tumor invades masticator space, pterygoid plates, or skull base; or encases internal carotid artery